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Summary.
The objective of the work presented in this thesis was the 
construction of an ELISA test for the detection of Mycoplasma 
bovis antigen in milk samples. Consequently, monoclonal 
antibodies to M^ _ bovis were prepared for use in the ELISA. Whole 
cell antigen was used to immunise two BALB/c or BALB/c hybrid 
mice from which serum and spleen cells were harvested. Fusion 
was carried out with NSO myeloma cell lines and 441 hybridomas 
were produced. One hundred and fifty-one of these produced 
antibody to an bovis antigen at levels twice background. The 
test used for detection and screening of hybridomas was an ELISA 
constructed with a membrane antigen of approximately 3 0 kD. 
Antigen for these bovis screening tests was prepared by the 
ultrasonic disruption of whole cell suspensions of M_j_ bovis grown 
in media containing mouse serum. The membrane fractions were 
harvested by ultracentrifugation at 34 000 g for 3 0 minutes,
resuspended in 10 mM TRIS-HC1 buffer, pH 7.8, treated with the 
chaotropic agent guanidinium thiocyanate (6.0 M) and dialysed 
against 6.0 M urea. The resulting solubilised antigen was 
designated antigen "i.p." and used in the screening ELISA . Six 
antibody-producing hybridomas were cloned further to produce 210 
stage-1 clones from which 6 monoclonal antibody lines were 
produced. Monoclonal antibody (MAb) "5G4" proved to be directed 
against media constituents but the remaining 5 were directed 
against M_j_ bovis antigen. MAb "5A10n contained IgGl with a titre 
in excess of Viooo anc* was selected f°r use i-n the final ELISA.
The final ELISA was constructed using MAb "5A10" as capture
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antibody at a dilution of 1/ 10o o *  The same antibody was 
biotinylated for use at 1/5qo as developing antibody.
O-phenylenediamine dihydrochloride was used as the substrate and 
2.5 M sulphuric acid as the stopping agent. It was evaluated 
against cultures of 34 isolates from 20 mycoplasma species. 
Absorption greater than twice background was only noted in the 
M. bovis and one M^ . agalactiae isolates. The occurrence of the 
same antigen in the two species does not prevent the use of this 
ELISA in the detection of M_;_ bovis in bovine mastitis as 
M. agalactiae does not occur in this species.
Serial dilutions of broth cultures of M^ _ bovis sc38, the 
strain against which the monoclonal antibodies were produced, 
were examined by ELISA and culture. The level of detection was
Q  , ,
found to be 10 cfu/ml. Milk samples from cows which had been 
infected experimentally with an East German isolate of M^ _ bovis 
were supplied by Dr H Pfutzner, Jena, in frozen form together 
with information about the numbers of mycoplasmal cfu present at 
the time of sampling. 78 milk samples from 6 cows were examined
for M_j_ bovis antigen using the ELISA, and for
N-acetylglucosaminidase (NAGase) using an ELISA available at 
Stormont. The ELISA detected bovis in milks which had an 
original concentration of 107 cfu/ml. ELISA results were 
positive for milks taken between days 3 and 21 (Cow 1); 7 and 38 
(Cow 2) ; 7 and 10 (Cow 3) ; 7 and 38 (Cow 8) ; and 7 and 10 (Cow
9) . Cow 7 was negative both by ELISA and culture. The NAGase
results were positive over a longer period than the Mj_ bovis 
ELISA results.
v
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Chapter One. 
Literature Review
1. Introduction.
A review of the current literature relating to JL bovis was 
undertaken, and is presented below. To date, no incidents of 
bovine mastitis caused by It bovis have been recorded in Northern 
Ireland, and the purpose of this study was to develop a rapid 
test for the detection of the organism. Consequently, the review 
details the general properties of the organism and the standard 
protocols for its identification. Details of the clinical 
presentation and pathology of bovine mastitis caused by M_i_ bovis 
are documented, including pertinent aspects of the 
immunopathological characteristics of the disease syndrome.
1.1 General properties
Mycoplasmas have no cell wall, are membrane bound, and are very 
small. They are the smallest micro-organisms which can multiply 
independently outside the cell. They can pass through bacterial 
filters, have a small genome and the guanine and cytosine ratio 
of their DNA (22 - 40 mol%) is generally lower than in bacteria 
(3) .
1.11 Characteristics of the mycoplasmas as a group.
The classification is based largely on serology and biochemical 
properties. Within the genera, the species are identified by 
their biochemical characteristics and especially by their surface
1
antigens which are demonstrated by growth inhibition and 
epifluorescence.
The single most important characteristic that distinguishes the 
mycoplasmas from other prokaryotes is their total lack of a cell 
wall, due to their inability to synthesise peptidoglycan and its 
precursors. Demonstration of a single membrane with a trilaminar 
structure in properly fixed and sectioned cells is an essential 
requirement for defining a new isolate as a mycoplasma (4). This 
anatomical feature is responsible for most of the peculiar 
properties of the mycoplasmas as a group:- 
Pleomorphology and plasticity;
Sensitivity to lysis by osmotic shock, alcohols, organic 
solvents, detergents, antibody and complement?
Filterability through 0.45 urn pore-diameter filters; 
Fried-egg colony shape?
Total resistance to penicillin and other antibacterial 
substances that degrade or specifically inhibit 
peptidoglycan synthesis.
Many of these features are shared by the L-phase variants 
(L-forms) of bacteria, in which the cell wall is either defective 
or is totally missing. The L-phase variants, which are usually 
laboratory artifacts, can revert to the wall-covered bacterial 
forms once the inducing substance (penicillin, lysozyme, 
antibody) is removed from the growth medium. The L-phase 
variants, unlike mycoplasmas, are capable of synthesising 
precursors of bacterial cell wall polymers and penicillin-binding 
proteins (3).
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The lack of a cell wall constitutes the basis for the inclusion 
of the mycoplasmas in a separate class: Mollicutes (mollis -
soft; cutis - skin) . The trivial term mycoplasmas has been used 
rather loosely to denote any species in the class Mollicutes. 
The mycoplasmas are the smallest self-replicating prokaryotes. 
Mycoplasma cultures contain coccoid cells that have diameters as 
small as 300 nm and are still capable of reproduction.
Mycoplasmas usually exhibit an extremely simple ultrastructure. 
The mycoplasma cell is bounded by a plasma membrane, and the 
enclosed cytoplasm contains ribosomes and a circular double­
stranded DNA molecule. The mycoplasma genome is typically 
prokaryotic with semiconservative replication. The protein- 
synthesising machinery in mycoplasmas is also prokaryotic in 
nature so that antibiotics such as chloramphenicol and the 
tetracyclines inhibit protein synthesis and growth. The 
mycoplasma membrane resembles the plasma membranes of other 
prokaryotes in being composed of approximately 2/3 protein and 
1/3 lipids. The mycoplasma lipids are mostly typical prokaryotic 
phospholipids and glycolipids, but the sterol-requiring strains 
contain, in addition, significant quantities of cholesterol. 
Membrane proteins, glycolipids, and lipoglycans exposed on the 
cell-surface are major antigenic determinants in mycoplasmas. 
Antisera containing antibodies to these components inhibit 
mycoplasma growth amd metabolism and deform cell shape and, in 
the presence of complement, cause lysis of the organisms. These 
phenomena serve as the basis for a variety of serological tests 
used to differentiate mycoplasma species.
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1.12Morphologv
The absence of a cell wall and the enclosure of the cell by a 
thin, 3-layered cytoplasmic cell membrane permit considerable 
pleomorphism. Granular, rod and filamentous forms are all 
recorded (3) .
1.13 Cultural characters and the isolation of mycoplasmas.
Mycoplasmas require isotonic media, containing growth factors 
which they are unable to synthesise, like cholesterol, fatty 
acids, some amino acids and certain components of their DNA. 
Basic media to which yeast extract, horse serum, DNA and other 
substances have been added must be used in order to satisify the 
requirements of the mycoplasmas (3).
1.14 Media for the isolation of mycoplasmas.
Mycoplasmas require cholesterol (contained in serum) for their 
growth, acholeplasmas do not. Antibiotics directed towards the 
bacterial cell wall (e.g. penicillin) are usually added to the 
media for selective culture of mycoplasmas. Many mycoplasmas will 
only grow, or grow better, under micro-aerophilic conditions. As 
a general principle, primary cultures are incubated 48 hours at 
37°C, in an atmosphere of 5 % C02 (3).
The assessment of solid-media colonies is done under the 
dissecting microscope with a magnification of x40. Typical
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pinpoint colonies show a more or less dense, darker granular 
centre which grows embedded in the agar and this is surrounded by 
a thinner, lighter veil-like surface zone ("fried-egg" form). 
One can assume that mycoplasma colonies are present if the 
typical colony picture is seen, there is no growth on serum-free 
media (Acholeplasmas are the exception), and the colonies adhere 
to the medium.
1.15 Identification of Mycoplasmas
A number of different procedures are required in order to 
identify mycoplasmas. The following are of practical importance 
(3):
1. Identification to family:
This relies upon the demonstration of the growth-inhibiting 
effect of digitonin (cholesterol analogue) on Mycoplasmataceae 
and on the demonstration of cholesterol dependence, which is 
tested in serum-free media containing fatty acids, albumin and 
cholesterol.
2. Identification to genus:
Mycoplasmas are urease negative: ureaplasmas can be distinguished 
from mycoplasmas by their ability to hydrolyse urea. This 
property is tested in media containing phenol red and 0.1% urea: 
if ureaplasmas are present, the colour changes within 24 - 48 
hours from yellow to red.
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3. Identification to species:
This may be carried out using biochemical tests in which a 
suitable medium, such as mycoplasma broth pH 7.0 - 7.3 , is
supplemented with glucose and 0.2% L-arginine, with phenol red 
as indicator of fermentation and arginine hydrolysis.
Biochemical characteristics are useful during isolation. Species 
identification relies on serological detection of specific 
antigens by the epifluorescence and growth inhibition tests. 
Epifluorescence is the technique of visualising the presence of 
antigen in tissue sections which have been incubated with 
specific antisera and subsequently developed using a fluorescent 
conjugate. Examination is then carried out using a fluorescence 
microscope. In the growth inhibition test, the aVaSence of 
colony development around an area containing species specific 
mycoplasma antisera allows identification to species level.
1.16 Incidence and veterinary significance of mycoplasma.
The mycoplasmas of veterinary significance parasitise the mucus 
membranes (HZ). They are found mainly in the respiratory and 
urogenital tracts, in the udder and joints, and they exhibit a 
relatively strict host specif icity (37). The pathogenicity of the 
different species of mycoplasma for animals varies considerably. 
Some cause recognised diseases, e.g. Contagious Bovine 
Pleuropneumonia (C.B.P.P.), whilst others cause no clinical 
signs, e.g. Mycoplasma gallinarum. This thesis is concerned with 
Mycoplasma bovis (M. bovis) - therefore the remainder of the 
review is devoted to consideration of the role of M^ . bovis in
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bovine mastitis, and to a review of the methods by which it can 
be detected (^3/SLl).
Mastitis is the most important condition caused by It bovis - 
this is followed in frequency by catarrhal pneumonia and 
refractory arthritis of calves and young cattle (31, 67) . It has 
been implicated as a cause of abortion (63). The mere statement 
that mycoplasmas have been demonstrated in a lesion is of little 
clinical value, because many species are entirely or largely non- 
pathogenic, even if they are isolated from a pathogenic lesion. 
Further identification is therefore often required in order to 
determine the significance and pathogenicity of an isolate and a 
multiplicity of sera are required for their serological 
identifications (3) .
2.1 Aetiology of Mycoplasma bovis mastitis.
2.11 Characteristics of M. bovis.
Order Mycoplasmatales
Family Mycoplasmataceae
Genus Mycoplasma
Species Mycoplasma bovis
Previously Mycoplasma agalactiae subsp. bovis, 
then Mycoplasma bovimastitidis -elevated to species 
rank 1976 on the basis of serology and 
nucleic acid homology studies (4, 5).
Coccoid and very short filamentous forms;
Growth of typical Mycoplasma "fried egg" colonies (0.2 mm) 
optimum about 37°C no growth at 28°C;
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mol % G + C of the DNA is 27.8 - 32.9;
the DNA/DNA homology between the type strain of this species and 
the type strain of Mycoplasma agalactiae is about 40%
Glucose catabolism -
Mannose catabolism -
Arginine hydrolysis
Phosphatase +
Tetrazolium reduction (Ae/An) +/+
Mol % G + C of DNA 27.8 - 32.9
2.12 History and Distribution
The first recognised outbreak of mastitis due to the species now 
called Mj. bovis. the most frequent cause of bovine mycoplasmal 
mastitis, occurred in Connecticut in 196l(ll|20, 21) . Because of 
the apparent similarity of this outbreak to that of contagious 
agalactia in goats and sheep caused by M^ _ agalactiae. it was 
suggested tentatively that the organism be called ML. agalactiae 
var bovis (39). In recognition of serological differences, M. 
bovimastitidis was suggested as a more appropriate designation
(39) . Based upon indirect ep» fluorescence, growth inhibition, 
metabolic inhibition, and nucleic hybridization observations, it 
was later recommended that these strains be regarded as a 
separate species, and that the new species be named IL bovis
(40) . Shortly following the original outbreak in Connecticut, 
mycoplasma mastitis was described in 16 herds in New York: the 
organism was demonstrated to be serologically similar to the 
Connecticut strain now called JL. bovis (4, 5, 39). An outbreak of
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mycoplasma mastitis occurred in Israel that was apparently due to 
M. bovis (20, 39) : mastitis due to M^ . bovis occurred in 1964 in a 
large herd in California (39, 41). Since this time, mastitis due 
to ^  bovis or isolation of M^ _ bovis from milk has been reported 
from Australia (20), England (39), Bulgaria (39), Canada (39), 
France (65) , Denmark (29) , Switzerland (70) , Hungary (39) , 
Germany (66), Italy (20), Netherlands (20, 21), Spain (20),
Portugal (20) and Yugoslavia (20). It would appear that the 
disease is spreading to, or being identified in, more countries. 
Most of the reported cases have been in the United States, where 
it has been widely distributed (z*)The greatest prevalence appears 
to be in California, where 104 herds have been involved in 
clinical mycoplasma mastitis outbreaks (43): M_;_ bovis was
involved in 59 of the outbreaks. M^ . alkalescens. M. arainini. M. 
boviqenitalium. M. bovirhinis. M. canadense, and 'strain ST-61 
(M. californicum) were also involved in these problem herds.
In 2 statewide surveys of bulk tank milk samples in California, 
pathogenic mycoplasmas were recovered from about 4% of the 
samples (39, 43). About 59% of the pathogenic isolates from the 
bulk tank milk samples were M_j_ bovis.
Five of the pathogens found in samples from clinical cases were 
found in bulk tank samples and in somewhat the same frequency,
i.e. 52% of the herds with bulk tank samples that were positive 
for pathogenic mycoplasmas were also positive for M^ . bovis.
Based on continuing observations it appears that mycoplasma 
mastitis is becoming more widespread in areas such as California, 
which has had the disease for some time, and in other places such
9
as England, where mycoplasma mastitis due to M_j_ bovis was 
described for the first time in 1978 (39, 76).
2.13 Economic aspects.
The economic impact of ML. bovis mastitis can be relatively mild 
if discovered when only a few cows are involved and if control is 
instituted immediately. 10% of the herd is usually infected by 
the time a diagnosis is made and usually not more than 25 - 30% 
of the cows are infected before the endemic disease is controlled 
(39). Morbidity of 10 - 70% and salvage sales of 1/3 of the cows 
from 14 herds with IL bovis mastitis have been recorded.
Additional cost following ML. bovis mastitis arises because the 
return to milk production may be quite variable in terms of both 
time and production. Consequences of infection listed below have 
been recorded:
a return to production after 3 - 4  weeks at much reduced 
yields (2 0);
reduced yield after 8 - 1 2  weeks if the onset was early in 
lactation, or drying off if the onset was more than 12 weeks 
into lactation (39) ?
no saleable milk for the entire lactation with recovery the 
next lactation, recovery after several months and apparent 
recovery, followed by relapse (39)?
50% loss of yield (39) ; poor yields in the subsequent
lactation from cows found infected during the dry period (39) ;
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massive decrease in production or agalactia (39);
generally poor performance in succeeding lactations (39) .
1 The total economic impact of It bovis mastitis varies greatly, 
I but can be considerable, depending upon the number and value of 
the animals involved, severity, milk loss, etc (?t.y
3.1 Clinical Characteristics.
Mycoplasma mastitis should be suspected whenever the following 
clinical signs are present:
1. A rapidly spreading increase in severe purulent mastitis cases 
that resist treatment, in cows that show little other evidence of 
illness;
2. Mastitis cases that typically involve more than 1 quarter 
(often all quarters);
3. Marked loss of production in affected quarters, most of which 
show severe mastitis, but some of which may simply cease 
lactating;
4. Abnormal secretions with tannish or brownish discolouration 
and sandy or flaky sediments in watery or serous fluid. 
Particles may rise to the top of the tube early in the clinical 
disease but usually sink to the bottom. After a few days the 
entire secretion may be seropurulent (40).
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Variable degrees of oedematous swelling and tenderness usually 
accompany M^ _ bovis mastitis (35). Although the inflammatory
swelling is extensive in some cows, in others it is very mild 
with agalactia predominating as a sign and quarters drying up. 
Often all 4 quarters are found to be infected (20, 39, 40, 41,
56) . Infection spreads from one infected quarter to the other 
quarter on the same side and then to the opposite quarters over a 
period of 1 - 3 weeks (39, 40, 41).
Mycoplasma can be demonstrated in large numbers in milk from 
infected quarters for 2 or 3 days before clinical signs or 
abnormal milk can be detected. For 3 or 4 days thereafter the 
milk may be thin or watery and flakes or sandy sediment may 
adhere to the sides of the sample tube, settle out upon standing, 
or rise to the top with the cream. Tannish discolouration is 
common at this time and milky fluid is gradually replaced by a 
seropurulent secretion during the next few days which may persist 
for weeks or months. Sometimes the secretion may be thick and 
resemble colostrum. M_j_ bovis can survive and multiply in milk 
with high somatic cell counts and infection occurs frequently in 
quarters already infected with other pathogens (39) .
There is great variation in severity and duration of the disease 
between and within affected herds. Some cows shedding mycoplasma 
in their milk are never observed to have clinical signs. Cows 
that appear to recover after several days or weeks can shed 
mycoplasma for a variable period of time, perhaps intermittently, 
for at least 13 months (39). This variable duration of clinical 
signs and shedder status contributes to difficulty in predicting
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the outcome of disease in infected quarters and determination of 
full bacteriological recovery. For this reason, cows that have 
been diagnosed positive for M_j_ bovis mastitis should be 
considered as positive possibly for life. In some outbreaks 
culture of the mammary secretions of dry cows is sometimes 
positive for mycoplasma. Most of these cows will not develop 
clinical disease until parturition, or possibly several days 
after parturition. Non-immune herds newly infected with ft bovis 
are likely to experience a high percentage of very severe cases. 
In some cows that are culturally positive there is often no 
history of past or present clinical mastitis (39).
The major cellular change in milk infected with M_*_ bovis is a 
very marked leucocytosis due primarily to neutrophils. Cell 
counts from natural M_;_ bovis infections vary from 
0.86 - 80.0 x 106 cells/ml in countable samples. In contrast to 
other forms of mastitis, casein nitrogen is greatly increased 
(39) .
3.2 The demonstration of M. bovis in milk.
M. bovis has been isolated from milk within 12 - 18 hours
following experimental infection with 105 - 1010 organisms. The 
usual excretion period is considered to be 2 months: it is known 
that substantially longer or shorter excretion periods may occur 
- a 13-month excretion period has been reported (39) .
The mycoplasma survive in milk for over 2 years at -20°C, 63 days 
at 4°C, 14 days at 20°C and 7 days at 37°C (83).
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Giemsa staining of milk films is not a reliable diagnostic method 
because the organisms may not be recognised even though present 
or particles resembling mycoplasma may be present in apparently 
uninfected milk. One staining technique for milk smears uses 
polychrome methylene blue. The organisms are metachromatic, 
appearing reddish purple against the blue background (39) . 
Another is to stain clinical milk samples with 0.01% acridine 
orange at pH 3.0 (38).
The literature cites the ELISA detection of bovine serum antibody 
specific to Ih bovis for use in epidemiological field studies of 
bovine mastitis (17, 33, 36, 64, 77, 80y 82). Varying degrees of
serological cross-reactivity to seven heterologous bovine 
mycoplasmal species were demonstrated: cross-reactivity was
minimized by preincubation of cattle sera with suspensions of 
heterologous mycoplasma antigens, prior to measuring serum 
antibody to solid-phase antigen (36). Heterologous absorption 
improved the immunological specificity of the assays while 
avoiding the need to prepare species-unique antigens (23). 
Cultural demonstration of M_j_ bovis initially involves 
i ‘noculation of 2.5 ml mycoplasma broth and incubation under 
standard conditions for up to 48 hours lMfc).The broth cultures are 
checked routinely after 24 hours for growth by placing a drop of 
the inoculated broth on solid 'Friis' agar, the latter itself 
being incubated overnight and then examined under a dissecting 
microscope for typical colonies after 24 hours incubation.
Methods for the demonstration of It bovis are further reviewed 
below (3).
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3.31 Pathogenesis and Pathology
The mechanism by which M_j_ bovis infection spreads from quarter to 
quarter is considered to be haematogenous, given the 
demonstration of mycoplasmaemia. Dipping teats in infected 
secretion once for 10 sec before milking was sufficient for 
infection, illustrating the high infectivity of this pathogen and 
its capacity for spread (39).
Gross and histological changes of acute, purulent, parenchymal 
mastitis are observed in affected quarters within 17 - 60 hours 
post intracisternal innoculation of M^ _ bovis cultures (39). At 
day 6 p.i. the infected udder quarters were swollen, their cut 
surface was yellowish-brown and granular. At 8 days p.i., the 
lymph nodes were swollen and the interalveolar connective tissue 
was infiltrated by lymphocytes, plasma cells and neutrophilic 
granulocytes. By 14 days p.i., the interalveolar connective 
tissue had undergone proliferation and showed a diffuse 
infiltration by plasma cells, lymphoid cells and granulocytes. 
The glandular alveoli had ceased to secrete milk. At 28 days 
p.i., both the infected and uninfected udder quarters were tough, 
firm, and the mucous membrane of the milk cistern was thickened 
and uneven. A variable amount of swelling and firmness of the 
quarter is almost always noticed early in the course of the 
disease. Later the swelling usually disappears and the udder 
tends to become flabby and slack (18) . At this time agalactia is 
marked and involution and atrophy of alveoli have taken place 
(39) . In cases that proceed to agalactia and involution without
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protracted or especially severe inflammatory reactions, permanent 
fibrotic lesions are probably minimal. In general, more severe 
and destructive inflammatory processes may be expected following 
infection during early lactation as contrasted with mid- or late 
lactation, when the tendency is more toward early agalactia, 
which persists until the next calving. Multiple abscess 
formation is not uncommon. When cut, the infected gland usually 
seems to be hard due to increased fibrosis (39).
M. bovis is also associated with bovine arthritis and pneumonia 
(31) . One may speculate that mycoplasmas might spread to the 
udder from other body or environmental sites without the 
necessity for udder-to-udder transmission. Clinical mastitis 
accompanied by mycoplasmaemia has been produced in cows following 
intracisternal ».noculation with various It bovis strains (18) . 
Haematogenous spread from the respiratory tract is a logical 
possibility, given the demonstration of mycoplasmaemia (39^ 78).
3.32 Microscrooic Pathology
The pathology, as with mastitis due to other pathogens, may vary 
considerably from lobule to lobule depending upon the presence of 
infection and the stage of the process. Neutrophils and some 
macrophages are found very early within the alveoli and ductal 
epithelium. Eventually cellularity decreases and mature fibrous 
tissue becomes prominent and may be interspersed with numerous 
abscesses of varying size. Fluorescent microscopy revealed the 
mycoplasma to be present in discrete colonies throughout the 
gland. In some areas all alveoli were replaced by an invasive 
and obiiterative fibrosis within fibrotic interstitial tissue
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(39) . Lymphocytes from calves inoculated with bovis antigens 
showed suppressed lymphoblastogenesis, suggesting that mycoplasma 
cell membrane morphology is similar to that of mammalian cells, 
and mycoplasma have been shown to incorporate environmental 
proteins, including antibodies, onto their surface membranes: it 
might be that the T-lymphocyte suppressor cells are functioning 
due to the similarity to host-tissue and/or the camouflage of 
mycoplasma-specific determinants by host antigens (39).
4.1 Resistance and Immunity.
It is common in infected herds to find shedding of mycoplasmas by 
animals with no history of typical mastitis. Herds in which the 
disease has been endemic for a long time may experience a milder 
form of disease and occasionally an outbreak may be almost 
entirely composed of mild clinical or non-clinical infections. 
Immunological resistance may be involved in such cases. Short­
term resistance to mycoplasma re-infection is mycoplasma-species- 
specific. Infections of the bovine mammary gland due to M^ _ bovis 
usually elicit substantial systemic antibody responses. However, 
increased indirect haemagglutinating (IHA) titres from previous 
naturally occurring M_;_ bovis mastitis infections, although 
indicative of recent exposure to the organism, do not prevent 
reinfection from experimental challenge exposure (11)* 
Therefore, bovine mammary infections with mycoplasma are somewhat 
analogous to mycoplasmal respiratory infections in that 
circulating antibodies do not appear to provide protection to 
current infection or against reinfection('s)4
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5.1 Epidemiology.
Many new outbreaks of ML. bovis mastitis can be traced to purchase 
or introduction of infected cows (20, 21, 39) . Outbreaks also
occur in "closed" herds, as recorded in some instances (20) . 
Recent introduction of infected animals is not always a precursor 
to mycoplasma mastitis outbreaks. A high prevalence of nasal 
carriers of M_i_ bovis occurs in young calves from farms having, 
or recently having had, Mj_ bovis mastitis problems (43, 67). 
Spread also occurs from treatment at drying-off or during 
lactation in infected herds. A common history is for cows to be 
diverted to a "hospital" group for treatment of conventional 
mastitis, from which they recover and then return a week or so 
later with mycoplasma mastitis. Mj_ bovis mastitis infection has 
been observed in non-lactating cows. Some become clinical while 
non-lactating; others were clinical upon calving. In such 
instances infected cows could sometimes be grouped according to 
certain drying-off treatment dates. Spread was believed to occur 
during this therapy.
Apparently recovered animals may remain continuous or 
intermittent shedders for many months, and even into the next 
lactation (39). Newly infected cows may shed mycoplasma in large 
numbers for several days prior to showing clinical signs. Such 
cows often serve as a possible source of infection in a
regular group of milking cows with spread within the herd being 
facilitated by the milking machine contamination inevitably 
resulting.
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A study of California dairy herds for the presence of pathogenic 
mycoplasma in bulk tank milk samples revealed a strong 
association with large herd size and a lesser association with 
higher percentage of cows leaving the herd (culled) (43). Herd 
size is important as a factor determining the prevalence of 
pathogenic mycoplasma in bulk tank milk. Other factors possibly 
related to epidemiology include stress, cold, inferior feeding, 
and airborne and genital spread (39).
Diagnosis.
In a situation where clinical signs and history are present as 
described above, and routine bacteriological examination of milk 
samples have not produced any isolations, mycoplasmal mastitis 
due to M^ _ bovis may be suspected. Confirmation of the diagnosis 
is achieved using the special techniques outlined above to 
demonstrate and identify the organism (3).
5.2 Therapy.
Investigators in most countries have concluded that there is no 
satisfactory treatment for M_j_ bovis mastitis. Intramammary 
therapy generally gives disappointing results. Italian workers 
claim good results from intramuscular injection of 5 g tylosin, 3 
doses at 3-day intervals. As with most mycoplasma infect»o«ts, the 
sooner after infection that treatment begins the better the 
prospects of a good response, and in infections more than 10 - 12 
days old, results tend to be very poor. The potential of the 
recently developed antibiotics danofloxacin and enrofloxacin have
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not yet been evaluated in a field outbreak of M_j_ bovis mastitis
L V 2) ■
5.3 Control.
The general principles of barrier control techniques have been 
applied to the few areas presently free of Mj_ bovis. Statut ry 
screening of all possible sources prior to entry to the country 
is presently achieved by cultural examination of semen etc. At 
the level of the individual herd a closed breeding policy 
prevents the introduction of the organism from bought in animals.
Once mycoplasma mastitis is diagnosed in a herd, identification 
of the specific cause is recommended since the clinical 
expectations may differ between mycoplasma species. Samples from 
all newly calved cows and all clinical mastitis cases in infected 
or suspect infected herds should be cultured for mycoplasma. 
Bulk tank milk should be monitored by frequent cultures for 
mycoplasma. Usually it is necessary to culture all the cows in 
the herd using composite samples in order to locate infected 
cows. If the outbreak is actively spreading, it is likely that 
some newly infected cows will not be discovered at the initial 
culture. Investigators have consistently recommended segregation 
or culling of infected animals^i^O, 39) .
6.1 The development of tests for the detection of mvcoplasmas.
A review of the epidemiology of M*. bovis mastitis reveals the 
highly contagious and pathogenic nature of the organism. 
Consequently, any control measures rely on the rapid, accurate
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identification of infected individuals. Another epidemiological 
feature which must be addressed by diagnostic tests is that 1 
intermittent shedding cow can give a cultural isolation from a 
bulk tank sample for the whole 300 cow herd. Thus the reasons for 
the development of the test are:
1. To confirm the identity of infected animals at the 
begining of a mastitis outbreak.
Effective control measures rely on the earliest possible 
identification of infected individuals, and their immediate 
isolation, so preventing spread throughout the herd.
2. To confirm carrier animals in outbreaks of mastitis.
Given the 13-month duration of intermittent shedding which is 
possible, regular routine screening of bulk milk samples is 
necessary to maintain herd surveillance.
3. To confirm the infected status of purchased, quarantine 
stock.
Preventing entry of infection to the herd is necessary by 
screening quarantined animals. The number of animals dealt 
with may be the individual dairy herd. Given the current
situation in Northern Ireland, the disease security of the 
national herd may be maintained by preventing the introduction 
of infection by importation - either of infected individuals, or 
of infected material such as semen (fcz).
The literature cites several strategies used to detect bovis 
involvement in clinical mastitis outbreaks:
1. detection of specific serum antibodies, assayed by 
complement fixation (CF), indirect haemagglutination (IHA) and
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ELISA (15, 17, 83) . The origin of infection giving rise to the
serum antibody may not necessarily be from the current 
mastitis challenge. Also given the intrinsic delay in 
production of an immune response, detection of serum antibody, 
even if specific, does not fulfil the demands of an
effectively early diagnosis.
2. direct isolation from samples (3);
The previously described isolation protocols take 3 - 7  
days for colony emergence - the species identification by
serological and immunofluorescence techniques must then follow. 
Again, this delay is not diagnostically satisfactory,
especially in dealing with the early stages of an outbreak.
3. detection of M^ . bovis antigens by crude ELISA (19, 63);
There is a recognised cross-reactivity problem in mycoplasma 
diagnosis, which may contribute to poor test sensitivity - as 
such, false negatives may occur if the test is crude, with 
obviously serious implications.
In this respect, the advantages of an antigen capture ELISA were
suitable for the development of a diagnostic test:
very high sensitivity and specificity potential of this assay
technique (especially appropriate in the context of the
recognised cross-reactivity problem of Mycoplasma);
rapid, simple assay;
feasible under field conditions;
exploits full potential of MAb technology.
Monoclonal antibodies, developed against a species-specific non­
cross-reacting epitope, were used to give maximum test 
specificity.
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Chapter 2.
Antigen preparation.
2.1 Introduction.
This chapter describes the preparation of Mj_ bovis antigens used 
for the construction of the ELISA and the development of 
monoclonal antibodies to antigenic determinants of 1L bovis as 
described in Chapters 3 and 4. The mycoplasma antigens used in 
classification of the organisms and in their detection are those 
associated with the cell membrane (39).
A variety of methods have been used to obtain mycoplasma antigens 
for use in ELISAs (16, 45, 57, 61) . The lack of a cell wall
makes mycoplasmas fragile and pliable organisms, susceptible to 
lysis by more gentle means than are usually suitable for 
disrupting bacteria with cell walls. Special attention must be 
given to harvesting and washing procedures in order to obtain a 
suspension of washed intact cells. Combined with the absence of 
intracytoplasmic membranes, this facilitates the fractionation 
of organisms into cytoplasmic and membrane fractions, eliminating 
the need for separation of the bacterial cell wall from the 
plasma membrane (16) .
The antigenicity of mycoplasmas varies with the age of the 
culture: for antigen preparation it is therefore preferable that 
organisms be in the logarithmic phase of growth. The antigens 
expressed on the mycoplasma membrane consist of proteins, 
carbohydrates and glycoproteins. All these types of antigen can 
theoretically be employed for use in the construction of ELISA 
tests - however, carbohydrate antigens may present problems in
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that they do not adsorb easily to polystyrene, the most commonly 
used carrier surface. For this reason protein antigens, or those 
composed primarily of protein, were used in this study.
Purification of Bacterial Membrane Proteins.
Proteins are major constituents of biological membranes. Although 
some membrane proteins have been successfully extracted and 
purified, most integral membrane proteins have not been 
accessible to standard techniques of biochemical fractionation 
(66) . In large part this has been due to the tendency of these 
proteins to aggregate in aqueous solvents. To facilitate the 
study of hydrophobic proteins, "chaotropic" agents have been 
used, which promote the solubilisation of many hydrophobic 
compounds in aqueous solvents. The order of effectiveness of 
these agents is:
thiocyanate (SCN-) > guanidinium+ > urea > chloride (Cl-)
The combination of the most efficient chaotropic anion and cation 
in the form of guanidinium thiocyanate is an effective 
solubilizer of membrane proteins (58) .
In this study the three main methods employed were "Sephadex" gel 
chromatography, ion exchange chromatography and guanidinium 
thiocyanate treatment (34, 58, 71).
Chromatography is the separation of solutes by percolation of a 
mobile phase through a stationary phase which selectively retards 
the solutes of the mobile phase. There are chromatographic 
techniques which achieve separation on the basis of various 
protein properties.
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Protein antigens from mycoplasma membranes can be separated by 
chromatography using techniques which operate using particular 
properties of the antigens - they are listed below:
Property Chromatographic technique
Size Gel permeation
I Charge 
| Solubility
| Immunological Activity
Reverse phase 
Affinity
Ion exchange
Ion exchange chromatography and gel filtration were used in this 
study. In ion exchange chromatography separation is obtained by 
reversible adsorption of the membrane fractions, the polarity of
exchange experiments are performed in two main stages:
1. Sample application and adsorption.
The sample is applied to the top of the column suspended in 
starting buffer and unbound substances are then washed from the 
exchanger bed using a column volume of starting buffer.
2. Elution and separation.
The separation is obtained since different substances have 
different affinities for the ion exchanger due to differences in 
their charge. These affinities can be controlled by varying 
conditions such as ionic strength and pH.
When using guanidinium thiocyanate treatment, crude membrane 
preparations are solubilised and used as an antigen for screening 
monoclonals produced by hybridomas. They were not used to induce
which depends on the eluting buffer. Ion
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monoclonal antibodies. The production of antigens from M^ . bovis 
by these methods is described below.
2.2 Materials and Methods.
2.21 Recovery of Whole Mycoplasma Cells.
The Mj. bovis isolate used in these studies was of Scottish 
origin, designated the Hsc38” strain. It was used for all 
subsequent antigen preparations, having been originally 
identified at the V.R.L. Belfast, and maintained by storage at 
-70°C. 20 ml of an actively growing culture were inoculated into
500 ml mycoplasma broth: incubation was for 48 hours at 37°C, in 
an atmosphere of 5% C02, at which stage a slight change in the 
phenol red indicator of the medium reflected maximum growth. The 
protocol for collection of this material was:
1. The cells were harvested by cold (4°C) centrifugation for 
20 minutes at 12 000 g.
2. The culture fluid was carefully discarded.
3. The cell pellet was re-suspended in cold isosmotic 0.25 M 
NaCl solution, to 2% of the volume of the growth medium.
4. The re-suspended cells were collected by centrifugation 
for 20 min at 12 000 g, at 4°C.
5. The cell pellet was washed twice more with cold isosmotic
0.25 M NaCl. 0.2 ml aliquots of this material were stored frozen 
at -20°C for future use.
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2.22 Preparation of Cell Fractions by Ultrasonic Oscillation.
Rupture of mycoplasma cells by ultrasonic oscillation was the 
most effective way of preparing mycoplasma-cell fractions and was 
carried out as follows:
1. Organisms in the logarithmic phase of growth were harvested 
and washed as described above. Protein determination was 
performed (51) on the washed cell pellet suspended in 0.025 M 
TRIS buffer, pH 7.5.
2. The suspension, diluted to 0.1 mg cell protein/ml was
immersed in crushed ice and sonicated for 1 minute, at 2 0
kilocycles/second, using an M.S.E. 150W ultrasonicator. The 
process was repeated twice, separated by 1 - 2 minute cooling 
periods.
3. The membranes were collected by centrifugation for 3 0 
minutes at 34 000 g: the supernatant was collected and
stored at -20°C as the "soluble cytoplasmic fraction"("C") for 
use in screening monoclonals (Chapter 4).
4. The membrane was resuspended in 2.0 ml standard buffer 
containing 10 mM TRIS-HC1, pH 7.8).
5. The solubilised membrane suspension was stored at -70°C
to prevent degradation of membrane phospholipids and
proteins by endogenous phospholipases and peptidases.
The mycoplasma membrane contains numerous proteins capable of 
acting as antigens. An attempt was made to separate these into 
groups using chromatographic techniques (gel chromatography, ion 
exchange chromatography) or exposure to a chaotropic agent. The 
aim of this was to reduce competition between different antigens
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in coating wells for the ELISA, thereby increasing the chances of 
obtaining monoclonal antibodies to more than one antigen type.
2.23 Purification of Membrane Proteins.
1. Gel filtration.
This was carried out by column chromatography, using a 100 cm 
column of 25 mm diameter, packed with Sephadex G100 (Pharmacia) 
or Sephadex G200 (Pharmacia) equilibrated with standard buffer at 
room temperature (71). Fractions were collected using an LKB- 
bromma ultrorac II fraction collector linked to an LKB-bromma 
2138 uvicord S spectrophotometer.
The ultrasonicated membrane fraction (in standard buffer from 
step 4 above) was solubilised by the addition of 10% Tween 20 
(Sigma) . 3 - 4 ml of the suspension was loaded onto the column
and elution fractions were collected at an absorbance of 280 nm 
(61) .
2. Anion Exchange Chromatography.
This was carried out using the column described above, packed 
with DE-52 anion exchange resin (Pharmacia) equilibrated with 
standard buffer. 3 - 4 ml of the ultrasonicated membrane
suspension, solubilised with 10% Tween 20 (Sigma), were applied 
to the column.
After applying the sample, the columns were washed with 250 ml 
of the starting buffer. This was followed by: (i) a stepwise
elution using 0.1 M, 0.2 M, 0.3 M, 0.4 M, 0.5 M and 1.0 M NaCl 
containing the TRIS component of the standard buffer.
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(ii) a continuous gradient from 0 - 0.5 M NaCl containing the 
TRIS component of the standard buffer, delivered from a gradient 
maker. The column was finally eluted with 200 ml of 1.0 M NaCl 
in the TRIS component of the standard buffer.
3. Guanidinium thiocyanate treatment.
Solid guanidinium thiocyanate was added to the membrane 
suspension to achieve a final concentration of 6.0 M. The degree 
of solubilisation is proportional to the concentration of 
guanidinium thiocyanate - maximal solubilisation was achieved at 
6 M of this "chaotropic" agent. This turbid suspension became 
clear during gentle agitation at room temperature for 30 
minutes. The entire mixture was centrifuged for 30 minutes at 
4000 g, 4°C. The supernatant fluid was immediately dialysed at 
4°C overnight against 100 volumes of standard buffer containing 
6 M urea until the pH of the solubilised cell membranes was equal 
to that of the standard buffer in 6M urea. The dialysate was 
then centrifuged for 30 minutes at 4000 g, 4°C and the pellet 
obtained by this step was combined with the earlier pellet and 
re-extracted with guanidinium thiocyanate in a similar fashion. 
The second extraction has been shown to solubilise an additional 
5 - 10% of the protein of the membrane suspension (58) .
Solubilisation may be determined by direct measurement of protein 
in the supernatant solution (51). In this study protein 
concentration was determined by spectrophotometry at 280 nm using 
an LKB-bromma 2138 uvicord S. The majority of the polypeptides 
appeared to remain in solution when the guanidinium thiocyanate 
was removed by dialysis against 6M urea.
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2.3 Results
1. Recovery of whole mycoplasma cells.
The method described above was found to yield 1 - 2 ml of cells 
per litre of culture. The system was found to be repeatable and 
two batches of cells were produced. 1 batch of 2 aliquots of 
whole cells was stored frozen for future use.
2. Preparation of cell fractions.
No problems were experienced with the method. A total of 10 x 
0.5ml aliquots of ultrasonicated cell membrane were produced for 
further work from the two batches of culture, and designated "M". 
10 aliquots of soluble cytoplasmic fraction were also produced, 
designated "C".
3. Results of separation of membrane antigens.
(i) Gel filtration.
The results of filtration using a Sephadex G Z00 (Pharmacia) 
column are shown in Figure 11. A major peak between fractions 3 
and 4 was the most obvious feature, but a subsidiary peak also 
occurred between fractions 4 and 5. All fractions were tested as 
antigen in the direct ELISA against hyperimmune serum described 
in Chapter 4.
Filtration using a Sephadex G200 (Pharmacia) column (Figure I. Si) 
also produced 2 major peaks. A repeat of this at a slower pump 
speed (Figure 2 ) also produced 2 major peaks, yielding
fractions 9 - 1 5  which were used as antigen along with fraction 
19 from the summit of the second peak.
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(ii) Anion exchange chromatography.
The results of stepwise chromatography are shown in Figures 3 J 
and 3||. Single peaks were demonstrated following each stepwise 
dilution, with the exception of the 0.4 M step which produced 2 
peaks. All fractions were tested as antigen in the ELISA 
described in Chapter 4. A repeat of this preparation (Figure 4) 
showed similar peaks following the stepwise inoculation of 
buffer. All fractions were tested for use as antigen.
The results of continuous chromatography are shown in figure 5. 
An initial peak is followed by a plateau and then by a second 
peak. All fractions shown were tested as antigen.
(iii) Guanidinium treatment.
Two 2 ml aliquots of treated material were produced and labelled 
antigen "i.p."
2.4 Discussion.
2.41 Recovery of whole mycoplasma cells.
The yield of cells was considered to be satisfactory. The ease 
with which the whole cells were processed in this study was 
fortunate. Highly viscous cellular DNA may be released from some 
of the cells during washing. Centrifugation may enhance the 
rupture of the cell membranes and release DNA. The released DNA 
is responsible for stickiness and aggregation of the cell pellet. 
Addition of deoxyribonuclease to the washed cell suspension can 
be used to overcome this difficulty (16), but was not required in 
this study.
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2.42 Preparation of cell fractions.
The crude cell fractions prepared by ultrasonication (cell 
membrane "M" and soluble cytoplasmic "C") may not be sufficiently 
pure for use as antigens without further processing. Ultrasonic 
oscillation is not recommended in enzyme location studies because 
the membrane is disintegrated into minute particles, some of 
which may not be sedimented even at very high gravitational 
forces. Therefore, the technique may cause contamination of the 
cytoplasmic fraction with minute membrane particles (16, 72) and 
render it unsuitable as a source of antigen. Similar questions 
arise about the purity of the membrane fraction. The criteria 
for membrane purity are arbitrary rather than absolute. A good 
membrane preparation should be as free as possible of unbroken 
cells, cytoplasmic constituents (ribosomes, DNA), and components 
of the growth medium (16).
The growth medium used in this study contained mouse serum, thus 
reducing one of the major sources of antigenic contamination. 
The use of chromatography was intended to produce protein 
antigens of higher purity on a repeatable basis free from 
unbroken cells and cytoplasmic constituents.
Gel permeation was successful in producing two main peaks of 
protein, but this was less specific than the use of stepwise 
anion exchange chromatography which, in turn, produced more peaks 
than gradient elution. Stepwise elution (using different salt 
molarities or pH changes) is technically simpler but has its 
disadvantages. Substances eluted by a sharp change in pH or 
ionic strength tend to elute close together and so peaks have
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sharp fronts and pronounced tailing since they contain more than 
one component. Tailing may lead to the appearance of false peaks 
if a buffer change is introduced too early. Linear salt or pH 
gradients help substances to be eluted in symmetrical peaks and 
give better resolution. There was no evidence that this problem 
occurred in this study.
Gradient elution generally produced good resolution. This is 
because during elution "zone-sharpening" occurs. In the absence 
of a gradient, one of the factors which would contribute to poor 
resolution would be band spreading as a result of diffusion. In 
gradient elution, the leading edge of a peak is retarded if it 
advances ahead of the concentration or pH required to elute it. 
Thus the trailing edge of the peak has a relatively higher speed 
of migration, resulting in zone sharpening. The total volume of 
eluent in the gradient used here was about x5 the bed volume of 
the ion exchanger. Longer gradients may lead to excessive band 
spreading and dilution, whilst shorter gradients may not give 
adequate separation. It is not clear whether the plateau 
following the first peak shown in Figure 5 was of this nature.
2.43 Guanidinium thiocvanate treatment.
Effective solubilisation of tightly bound membrane proteins was 
achieved by the use of the chaotropic agent, guanidinium 
thiocyanate. Further protein fractionation is difficult in the 
presence of the high ionic concentrations used. The polypeptides 
remain soluble when guanidinium thiocyanate was replaced by urea 
(58) . This would make possible the use of fractionation 
techniques depending on charge differences of the different
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polypeptides, such as ion exchange chromatography and 
polyacrylamide gel electrophoresis. The antigen produced here 
was used for these purposes but the information is not included 
in this thesis as the "i.p." fraction produced was used directly.
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Chapter Three. 
Production of Polyclonal and Monoclonal Antibodies to Mycoplasma 
bovis.
3.1 Introduction•
This chapter describes the production of the immunological 
reagents used in the study. Both hyperimmune sera and monoclonal 
antibodies were produced, the latter both as ascites fluid and as 
tissue culture supernatants.
The reasons for the use of monoclonal antibodies in the ELISA 
detection of mycoplasma antigens in milk were given in Chapter 1, 
but are restated here: monoclonal antibodies are specific to
individual epitopes and therefore avoid the cross-reactions so 
common in polyclonal sera to mycoplasmas; sensitivity, of 
particular importance for the detection of carriers and 
production of the large quantities necessary for a herd-screen 
type test. Monoclonal antibodies are produced from splenic 
B-lymphocytes of mice which have been stimulated by priming with 
antigen in vivo. B-lymphocytes can be activated to produce 
antibody specific for an antigen, but are very short lived in 
culture. Myeloma lines grow indefinitely in vitro but have lost 
their ability to produce immunoglobulin. The development of 
monoclonal technology by Kohler and Milstein (47) solved the two 
main problems:
1. Developing lines of myelomas that did not secrete any 
antibody of their own;
2. The development of a system of separating fused hybrids from
35
unfused myeloma and spleen cells. In their original paper, Kohler 
and Milstein used Sendai virus as the fusion agent. This virus 
has the ability to cause the two membranes to fuse. Later it was 
found that polyethylene glycol (PEG) would do the same thing but 
was much easier to handle, and it is now accepted as the fusion 
agent ("fusogen") of choice.
The variables that are involved during a fusion are cell ratio, 
medium, conditions for achieving contact, the fusion agent, time, 
temperature and processing after fusion.
The method developed for the separation of fused hybrids from 
unfused cells makes use of myelomas defective in the enzyme 
hypoxanthine-phosphoribosyl-transferase (HPRT): unfused cells die 
in medium that contains hypoxanthine, aminopterin and thymidine 
("HAT" medium) . The aminopterin blocks the main pathway of DNA 
synthesis, and the rescue pathway using exogenous hypoxanthine 
and thymidine depends on the presence of HPRT. Spleen cells die 
in culture and the unfused myeloma cells die in HAT medium: the
only cells that will survive are the hybrids in which the myeloma 
provides the ability to grow in culture, and the spleen cell 
provides the HPRT.
3.11 Antibody Purification.
Proteins are made up of an assortment of 20 amino acids. The 
choice, repetition and arrangement of these amino acids is unique 
to each protein. In the process of protein formation, as the 
primary chain of amino acids is assembled, so the secondary
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conformation (an alpha-helix, or beta-pleated sheet), is assumed. 
The folding of these sequences in relation to each other forms 
the tertiary structure. Non-protein groups added to the final 
protein give glycoproteins in the instance of carbohydrate 
chains. The primary structure is held together by the covalent 
peptide bonds between the amino acids. The covalent bonds 
stabilise the tertiary structure. The secondary and tertiary 
structure is further stabilised by hydrogen bonds and 
electrostatic forces. These interactions are dependent on the 
environmental conditions - changes in pH, ionic strength and 
temperature will interfere with them, thus changing the tertiary 
structure and changing the biological activity. Therefore when 
working with proteins, the conditions should be such that their 
tertiary structure is not irreversibly interfered with, so that 
they are able to maintain their natural, active form (1).
Purification of murine MAbs from ascites fluid or culture fluid 
is an essential step in the scheme of MAb production and 
characterisation, so producing an homologous antibody class, 
directed against a specific epitope (52).
3.12 Purification of IoG by Protein A Affinity Chromatography.
Protein-A (SpA) is a cell-wall constituent of Staphylococcus 
aureus. which has gained increasing importance as a tool in both 
quantitative and qualitative immunological techniques because of 
its ability to interact with immunoglobulins, mainly IgG, from 
mammalian species. Such applications mainly employ SpA in the
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insoluble state as SpA-Sepharose. Fractionation on SpA-Sepharose 
provides a simple way to produce murine IgGl uncontaminated by 
other murine IgG subclasses (50, 71).
The SpA molecule is divided into 2 structurally and functionally 
different regions: a region consisting of highly homologous 
immunoglobulin-binding units, and a non-immunoglobulin binding 
unit covalently linked to the cell wall. SpA remains markedly 
stable on exposure to high temperatures, low pH and denaturing 
agents, e.g. guanidine-HCl (50).
SpA interacts with IgG via the Fc part of the immunoglobulin. 
Differences in the affinity for SpA of different subclasses of 
IgG is reflected by the different pHs needed for elution from 
SpA-Sepharose columns, which have been utilised in separating 
different subclasses from each other (34).
The value of SpA as a reagent in laboratory techniques is 
lessened due to some defects in its Ig-binding reactivity: 
mouse immunoglobulins have a low affinity for SpA; 
lack of Fc reactivity with IgG 3, a subclass constituting 
approximately 8% of total IgG (30) .
3.13 Protein-G.
Protein-G (SpG) is the IgG-binding protein of group C and G 
streptococci. The molecule binds IgG of different subclasses 
from most mammalian species and thereby has a broader IgG-binding 
capacity than SpA. SpG also has a higher affinity for murine IgG 
than SpA (1, 2, 13, 73).
The unique IgG-binding properties displayed individually by SpA
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and SpG are combined in the chimaeric Protein-AG consisting of 
the IgG-binding domains of both SpA and SpG. SpA and SpG have 
complementary binding patterns - the chimaeric receptors retain 
the binding capacities of both the parental constituents. The 
advantages are:
the binding spectra toward polyclonal immunoglobulins are broader 
than the individual parent proteins;
individual subclasses of mouse monoclonals are more likely to 
possess strong affinity to the chimaeras than to SpA or SpG 
itself (27, 28).
In 1960 it was reported that under acidic conditions, plasma 
proteins could be differentially precipitated by short chain 
fatty acids, such as caprylic acid (n-octanoic acid) (25]frg). Based 
on this observation a procedure was developed in 1969 to isolate 
IgG from mammalian sera. It has been adapted for the isolation 
of monoclonal antibodies from mouse ascites fluid (69, 74).
3.2 Materials and Methods
Both hyperimmune murine serum and hybridomas for monoclonal 
antibody production were produced from the same two mice.
3.211 Production of immune mice
Two BALB/c o* BALB/c-hybrid mice from a colony known to have no 
serum antibody to Mj_ bovis were used. They were immunised with 
M. bovis sc38 whole cell antigen which consisted of washed
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cells, 50 - 100 fold concentrated from a broth culture using 20% 
murine serum, disrupted by ultrasonication, as described in 
Chapter 2.
100 ug of washed cell antigen in Complete Freund's Adjuvant was
injected into the peritoneal cavity, followed by 100 ug of washed
fi JjoVAnV
cell antigen in Incomplete Freund's 14 days later, again 
intraperitoneally. This was followed 2 months later by an 
intrasplenic boost of 100 ug of washed cell antigen alone. 
Hyperimmune serum was prepared from blood harvested by tail 
bleeding from the immunised mice, and stored at -20°C until 
required (59).
3.212 Harvesting of primed splenic cells
Three days after the final, intrasplenic, inoculation the mouse 
was killed by cervical dislocation and placed on its right side 
so the spleen was uppermost. The body was swabbed with 70% 
ethanol. An incision was made in the body wall to expose the 
spleen, without puncturing either the gut or the surrounding 
splenic arteries and veins. The spleen was removed, placed in a 
sterile petri dish and transferred to a sterile hood. Using 
sterile 21 G needles, the spleen was teased apart, in 2 ml of 
PBSJ medium, to release the cells. As the medium became cloudy 
it was pipetted off into a 10 ml centrifuge tube. The whole 
organ was broken down in this way.
Once the debris settled out, the supernatant was pipetted off 
into another tube. This was made up to 10 ml with more PBS A and 
the cells counted: 50 ul of supernatant-cell- suspension + 450
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ul 1% acetic acid in PBS, were added to 500 ul 0.2% Trypan Blue. 
The mixture was counted using a Neubauer haemocytometer. The 
counting chamber was divided up into 9 large squares: the centre 
square was subdivided into 25 whilst the surrounding 8 squares 
are subdivided into 16. All the viable cells in one of the large 
squares were counted. Non-viable cells are blue while cells 
lysed by the 1% acetic acid are red. The number of cells counted 
was multiplied by 104 and then by 20 (50 ul added to 950 ul) ,
giving the number of cells in 1 ml of the original suspension. 
The cells were washed twice in serum-free medium with 30 iM HEPES 
buffer. The cells were centrifuged at 1500 rpm/500 g for 10 
min between washes (75) .
3.213 Preparation of the myeloma cells
The NS0 myeloma cells (BALB/c-derived myeloma line) used were 
removed from liquid nitrogen and thawed out at least 1 week 
before the fusion. The myeloma cells were taken from the storage 
vessel and rapidly thawed out in a waterbath at 37°C. 5 ml of 5%
foetal calf serum (FCS) was then added to the tube a drop at a 
time over a period of about 5 mins whilst the tube was shaken. 
The cells were then washed once in medium and put into a 500 ml 
flask. The medium used was RPMI 1640 Origen (IGEN, USA) . The 
cells were then split the day before the fusion and resuspended 
in 250 ml flasks to 3 x 105 cells/ml. The next day they were at 
the exponential phase of growth and ready for fusion.
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3.214 MAb Fusion.
Three days after the final intrasplenic inoculation, the spleen 
cells were fused with exponential-growth-phase NSO myeloma cells, 
and the hybridoma cells maintained in RPMI 1640 medium 
supplemented with 20% gamma-globulin free horse serum (
The myeloma cells were harvested and counted using Trypan Blue. 
They were washed twice in serum-free HEPES buffered RPMI. The 
spleen and myeloma cells were mixed in a 10 ml tube at a ratio of 
10 viable spleen cells: 1 viable myeloma cell and spun down. The 
supernatant was removed and the tube placed in a 37°C waterbath. 
1 ml warm polyethylene glycol (PEG) was slowly added to the cells 
over a period of 1 min, with continual stirring. The cells must 
not be in contact with the PEG for more than 2 min. 1 ml of 
serum-free medium was immediately added, a further 4 ml serum- 
free medium over 3 - 4  min run down the side of the tube. 20 ml 
serum-free medium was added followed by 20 ml medium + 15% FCS. 
This medium was buffered with sodium bicarbonate. This mixture 
was left at 37°C for 1 - 2  hours. 0.5 ml of a suspension of 
macrophages were added per 25 ml of hybridoma cell suspension as 
feeders (46).
3.215 HAT Selection.
24 hours later, 1 ml of medium with x2 [HT] + 10% FCS was added 
to each well. 1 week later, 1 ml was removed from each well and 
replaced with 1 ml medium with xl HAT + 10% FCS. 2 weeks later, 1 
ml was removed from each well and replaced with 1 ml medium with 
xl HT + 10% FCS. Every week after this the medium was changed
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using RPMI 1640 + 10% FCS + sodium bicarbonate. During this 
period the unfused spleen and myeloma cells died in the HAT 
medium. Usually the hybridomas started to grow by the second 
week and grew rapidly once the HT was added. The medium turned 
yellow when the hybrids were growing well, and they were screened 
at that point.
3.216 Crvopreservation of Cells.
Sometimes hybridoma cells ceased antibody secretion for no 
apparent reason, so it was important to be able to go back to a 
vial that was frozen down soon after cloning Cells of second 
clone hybrids, secreting to high titre, were frozen down at the 
earliest opportunity to guard against clone contamination or 
incubator failure. The earliest time for consistently successful 
freezing is known to be after the first cloning. Subsequent 
aliquots of cells were frozen at regular intervals and stored in 
liquid nitrogen. The freezing mixture used was:
FCS 90%
DMSO 10%
The mixture was kept on ice, as DMSO is toxic to cells at 
temperatures > 4°C. The cells were harvested from 2 confluent 
'Linbro' wells, and spun for 5 min at 1000 rpm. The cells were 
counted and resuspended to 0.1 - 5.0 x 106 viable cells/ml in 
freezing mixture, and 1 ml aliquots were pipetted into cryostat 
tubes and placed in the freezing machine immediately. The 
cooling profile was:
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0°C to -30°C at 1.0°C/min 
-30°C to -60°C at 2.0° C/min
with subsequent transfer into liquid nitrogen. When required, a 
37°C waterbath was used to thaw the cells rapidly. 10 ml (1640 
RPMI + 10% FCS) was added quickly to dilute out the DMSO as it is 
toxic to the cells at temperatures above 4° C. The cells were 
then spun down and the supernatant decanted, removing the DMSO. 
The cells were re-suspended in fresh medium (59).
3.217 Hvbridoma Screening.
The hybridomas produced by the method above were screened for 
antibody production. The 2 most suitable assays for soluble 
antigens are the ELISA and "Dot Blot" assays. The ELISA method 
is more suitable for quantitative investigation and Dot Blot or 
Immunoblot techniques for qualitative assay. Soluble antigen is 
bound to either the plastic of a 96-well plate (ELISA) , or to 
nitrocellulose paper (Dot Blot). Monoclonal supernatants are 
incubated with this bound antigen and those containing specific 
antibody will bind to it. An enzyme-linked secondary antibody 
with specificity for the monoclonal immunoglobulin (anti-mouse 
Ig) is used to detect wells/dots where the primary monoclonals 
have bound. This binding is then visualised by the addition of 
an appropriate enzyme substrate which yields a coloured product 
after reaction with the enzyme. Where peroxidase-linked 
antibodies are used: the substrate opDD (O-phenylenediamine 
dihydrochloride) is used for ELISA (soluble reaction product), 
and DAB (Appendix) for Dot Blots (insoluble reaction product).
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There are several parameters to be determined before the assay 
can be used:
1. The antigen titration required to produce an optimal reaction
(colour change). For ELISA, this is usually in the range of
5 - 5 0  ug/ml of protein adsorbed onto the plate. Dot Blots
usually require a more concentrated antigen solution.
2. A blocking step may be required. For Dot Blots, blocking is 
essential, but for ELISA it will depend on the antigen. 
Insufficient antigen will not saturate all the binding sites and 
non-specific antibody-plastic binding will occur, constituting a 
false-positive.
3. The optimal dilution of second layer, conjugated antibody 
must be determined to minimise background levels. These initial 
parameters are determined from a titration of antigen against a 
known antibody - either a polyclonal antibody specific for the 
antigen, or the serum from the immunised mouse diluted to an 
optimum working dilution (about 10 ug/ml) protein as in a 
hybridoma supernatant (46).
3.218 ELISA Construction.
An ELISA was used to screen hybridoma supernatants. It was 
constructed and used as follows (19). The ELISA was carried out 
in microtitre trays using 100 ul volumes of each reagent per 
well. The optimum dilution of each reagent was established by 
titration. The plates were coated at 4° C overnight with a 
V 4000 dilution of the "i.p." antigen All incubations were at 
37°C and after each incubation stage, the wells were washed with
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5 changes of 0.01 M PBS pH 7.2, containing 0.05% Tween 20. The 
stages following coating were as follows:
1. test sample for 1 hour;
2. peroxidase-labelled goat-antimouse immunoglobulin (GAM);
3. substrate: 0.4 mg 0-phenylenediamine dihydrochloride/ml + 0.4
ul/ml (v/v) 30% H202 in 0.1 M citrate/phosphate buffer,
pH 5.5, for 15 min;
5. The substrate reaction was stopped by the addition of 50 ul 
2.5 M H2S04 per well;
6. Absorbance measured at wavelength 492 nm on an ELISA plate- 
reader (Titertek).
3.220 Cloning techniques.
The cloning of the selected wells is necessary because although 
positive, it is likely that there will be more than one clone of
cells in the well. There are 3 techniques available for cloning:
1. "Limiting Dilution" - where the cells are diluted out in the 
wells of a 96-well microtitre plate until they are diluted down 
to a theoretical 0.3 cells/well after the second and third 
cloning. The antibody from a well should then be the result of a 
single hybrid alone.
2. "Soft Agar Cloning" - where the cells from the positive well 
are mixed in agar and allowed to grow. The agar stops the cells 
from moving around so the little clumps of cells that form from a 
single clone may be visualised by a microscope. These cells are 
then removed from the agar and cultured.
3. "Sirk)I e-cell Manipulation" - where the cells are diluted out
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and single cells picked up and plated out.
Of the 3 methods, "Limited Dilution" is the easiest and quickest, 
but the single cell manipulation is probably more accurate and 
need only be done once (46).
3.221 Cloning by Limiting Dilution.
There are two methods that can be used for limiting dilution. 
Either the cells can be diluted to a set concentration and plated 
out in a microtitre plate to give a theoretical 0.3 cells/well, 
or, starting with a higher concentration of cells, they may be 
titrated across a microtitre plate so that only the last 2 
columns will be at less than 1 cell/well. This latter method is 
easier to perform and also eliminates the risk of losing a clone 
due to the slow growth that sometimes occurs when the cells are 
plated out at a very low density. Not all the wells will contain 
single clones, even when they are titrated to such low 
concentrations. The only way to be absolutely certain of a pure 
clone is inspection of the wells regularly as they start to grow 
up. This is very time consuming, but it does eliminate the 
necessity of repeating the cloning yet again. It is important to 
second-clone as early as possible to avoid the clone being 
overgrown by a non-producer.
3.222 Cloning: Limiting Dilution by Set Concentration.
This was the technique chosen for this study. The hybridoma 
cells were distributed by dilution in standard medium (RPMI 1640 
+ 20% serum) to achieve 0.5 cells/well, i.e. 1 cell every other
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well. The well containing hybridoma cells secreting ELISA- 
positive supernatant was harvested and counted. This was done by 
adding 50 ul of the cell suspension to 50 ul Trypan Blue and 
pipetting some of the mixture into a Neubauer haemocytometer (the 
counting chamber is divided into 9 large squares; the centre 
square is subdivided into 25, whilst the surrounding 8 squares 
are subdivided into 16; all the cells in one of the large 
squares are counted) . The number of cells (or an average of 4 
counted squares) is multiplied by the following factors: 
x 104 for 1 mm2 area
x 2 50:50 cells:Trypan blue dilution
Cloning 2 plates required 100 cells in 40 ml standard medium 
(RPMI 1640 + 2 0 %  serum).
Counting gives, for example, a cells/mm2 
= (a) x (2) x (104) cells/ml 
= (20a) x (103) cells/ml
10 ul of a suspension containing 20a x 103 cells/ml were added to 
10 ml standard medium to give 20a cells/ml, thus making pipetting 
off 100 cells manageable and accurate. 100/20a ml of the cell 
suspension were added to 40 ml standard medium, thus achieving
0.5 cells/well, covering 2 plates with 100 cells/40 ml.
A macrophage suspension was added to the cells as a feeder layer 
(0.5 ml macrophage suspension/9 6-well plate). 200 ul of the
cell/macrophage mix was added to each well of the plate. ELISA
screening of the supernatant fluid of these 'stage-1 clones' 
started 2 weeks later. Wells selected as positive were cloned 
again by the same protocol (46).
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3.223 Bulk production of Monoclonal Antibody (MAb).
There are 2 ways of producing large volumes of MAb:
1. Simply grow the cells in large flasks/bags and harvest the 
supernatant produced. Culture supernatants have only 10 ug/ml 
antibody, which may be concentrated in a variety of ways.
2. The hybridomas may be used to produce ascites fluid, in which 
the antibody concentration is usually 10 - 20 mg/ml.
Both methods were used in this study.
3.224 Production of Sac Fluid
This method of producing large amounts of antibody is achieved by 
growing the cells in "Costar" plates which have larger wells, 
then transfering the growing cells to an osmotic tube bathed in 
growth medium and incubated under standard conditions. The 
monoclonal antibody is secreted into the tissue culture 
supernatant.
3.225 Production of Ascites Fluid.
Hybridomas will grow in the peritoneal cavity of animals of the 
same strain as the tumour cell- line donor and spleen cell-donor, 
and secrete monoclonal antibody into the ascites fluid formed 
within the peritoneal cavity. The ascites fluid will also 
contain a proportion of immunoglobulins from the recipient 
animal.
Each MAb cell line was injected (0.5 ml, 2.0 x 106 cells/ml) 
intraperitoneally (i/p) into a single BALB/c mouse 4 days after
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the priming of the mouse with 0.5 ml Freund's incomplete 
adjuvant, "Pristane" (4,6,10,14-tetramethylpentadecane)(92). The 
developed ascites fluid was removed as the abdomen swells and 
clarified by centrifuging 10 min at 500 g and stored at -20°C. 
The MAb produced in ascites fluid can be purified to 10 mg/ml by 
the same methods as for the cell culture supernatant. The mouse 
was exsanguinated at euthanasia to for allow serum antibody 
collection (59, 75).
3.231 Purification of IgG by Protein A Affinity Chromatography.
This method makes use of the fact that Protein A from 
Staphylococcus A will bind the Fc portion of a number of IgG's of 
animal origin at high pH but not at low pH. Protein A is linked 
to Sepharose CL 48 beads with a low pH buffer - this type of 
separation is termed affinity chromatography (30). Ascites or 
hybridoma supernatant must first be purified by salt 
fractionation.
Salt fractionation was carried out using 10 M TRIS to adjust the 
pH of the Ig to 8.0 - 8.5. The Protein-A column was equilibrated 
with phosphate buffer, pH 8.0. After collecting the first 
elution volume, 0.1 M citrate butter, pH 4.0,was added to the 
top of the column. The second IgG (ph 4.0) elution fraction was 
collected. The non-bound (pH 8.0) fraction constituted the first 
elution volume. To avoid low pH damage to the IgG, the bound 
fractions were neutralised with 1.0 M TRIS. The sample was 
desalted using a G25 column to remove the salt ions, and 
transferred to PBS, pH 7.2.
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3.232 Partial purification of Ig by Salt Fractionation.
This method constitutes the first, basic clarification of any 
antibody. As the salt concentration of the medium is raised, 
there is interference with the interaction of water molecules 
with the charged polar groups on protein molecules, rendering 
them less hydrophilic. This allows a greater hydrophobic 
interaction between protein molecules and so they eventually 
become insoluble. The salt concentration at which each protein 
precipitates is different, but between closely related molecules 
such as immunoglobulins, the difference is not sufficiently great 
to give a high grade purity of precipitate. However, it is useful 
as a first step as many unwanted serum proteins, such as albumin, 
will remain in solution when immunoglobulins are precipitated 
(52) .
An alternative method to the long process of dialysis is to use a 
G25 column - it will allow salt ions to enter the beads but will 
exclude the much larger antibody (M.W. 150 000) . As the path
through the beads is much further that the path around them, the 
antibody will be eluted in PBS and so will have been dialysed. 
After dialysis, a Protein-A column may be used to purify the IgG 
fraction.
Using caprylic acid, the majority of plasma proteins are 
precipitated without affecting IgG. After caprylic acid 
treatment of ascites fluid or spent culture medium, the 
immunoglobulin may still contain an undesirable amount of albumin 
which can be removed by DEAE-cellulose chromatography. However
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each immunoglobulin elutes from DEAE-cellulose at an ionic 
strength characteristic for that particular MAb.
MAb was purified from mouse ascites fluid using a combination of 
caprylic acid and ammonium sulphate treatments. Ascites fluid 
was treated with caprylic acid (n-octanoic acid) (69) while 
adjusting the volume of each reagent proportionately depending on 
the starting volume of pooled ascites fluid.
Ammonium sulphate was used, at 4°C, to precipitate 
immunoglobulins. The MAb was dialysed overnight against PBS, pH 
7.2. The saturated ammonium sulphate solution was added very 
slowly at 4°C while stirring to a final 50%. The mixture was 
stirred at 4°C for a further 30 min, then centrifuged for 30 min 
at 3000 rpm. The supernatant was discarded and the precipitate 
resuspended in a very small volume of distilled water and 
dialysed twice agains PBS (52).
3.233 Purification of monoclonal antibody from ascites fluid.
1. Serum or ascites fluid was diluted with 4 vols. of acetate 
buffer (60 mM, pH 4.0), and the pH adjusted to 4.5.
2. Caprylic acid (25 ul/ml of diluted sample) was slowly added 
dropwise with thorough mixing: the solution was stirred for an 
additional 30 min. The MAb-containing supernatant was separated 
(from insoluble material: albumin and other non-IgG proteins) by 
centrifugation at 10 000 g for 30 min at 5 C and dialyzed
against 100 vols of phosphate-buffered saline (137 mM NaCl, 2.6 
mM KC1, 10 mM sodium-potassium phosphate buffer, pH 7.4,
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containing 0.2 mM EDTA) at 5°C.
3. The supernatant was mixed with 10 x concentrated PBS (10 
parts supernatant to 1 part 10 x PBS) . The pH was adjusted to 
7.4 with 1.0 N NaOH.
4. The supernatant was cooled to 4°C and fractionated with 
ammonium sulphate (0.277 g/ml to give 45% saturation). The 
sample was stirred for 30 min before the precipitated IgG was 
collected by centrifugation (5000 g for 15 min).
5. The supernatant was discarded, and the IgG pellet resuspended 
in a small volume of PBS (about 1/10 of the original volume of 
serum or ascites fluid was routinely used).
6. The resuspended IgG was dialyzed overnight against 100 vols. 
PBS.
7. Finally, insoluble material (usually a negligible amount) was 
separated from the purified immunoglobulin by centrifugation at 
8000 g for 15 min.
8. Purified MAb were stored at -20°C.
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3.234 Outline of the procedure to purify IgG. 
Serum or ascites fluid
Caprylic (n-octanoic) acid precipitate
• • 
supernatant #1
•
pellet #1
Ammonium Sulphate precipitation 
•
•
•
pellet #2 
Purified I9G
supernatant #2
3.241 Qualitative evaluation of the monoclonal antibodies
produced to M.bovis
This was carried out by Immunoblotting (81). Membrane antigen 
was prepared as described in Chapter 2 <2M).
3.242 (SDS-PAGE).
SDS is a detergent which efficiently solubilizes bacterial 
membrane proteins. In addition a reducing agent, 2- 
mercaptoethanol (2-ME), can be added to break the disulphide 
bridges. Charge differences between proteins are negated, and 
they move in the gel only on the basis of their molecular weight 
- the other individial differences due to their tertiary and 
quaternary structure are rendered unimportant. SDS-PAGE using a 
modified Laemmli discontinuous buffer system can be performed on 
a slab gel. In slab-gel electrophoresis, the gel is prepared 
between 2 plates. A 2-stage system is used - proteins initially 
run into a "stacking-gel", allowing the proteins to concentrate 
into a single tight band before enterig the stacking gel. This 
gives good resolution in the separating gel. Since the gel 
actually fractionates the proteins by their molecular weight, the 
choice of polyacrylamide concentration greatly influences the 
range of molecular weights that can be fractionated. 10% is the 
commonest concentration of polyacrylamide - lower concentrations 
are more useful for the separation of high molecular weight 
proteins and higher concentrations are used for the separation of 
proteins and peptides of lower molecular weight. The technique
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is useful to test the purity of Ig after ammonium sulphate 
precipitation and Protein-A column purification (16).
3.243 "Western Blotting”.
This is a method of characterising antigens with MAbs, which is 
simpler than immunoprecipitation and does not involve using 
radioactivity. The technique involves transferring the proteins 
from the gel onto nitrocellulose paper,sections of which can be 
incubated with the monoclonals and finally developed using anti- 
mouse-Ig Horse Radish Peroxidase (Sigma).
SDS-PAGE was carried out with mycoplasma fractions on 10% slab 
gels with 5% stacking gel. Strips were removed for protein 
staining and the remainder of the gel applied to a nitrocellulose 
sheet and blotted overnight at 17 mA/cm. Strips of 
nitrocellulose sheet from each fraction were blocked with 1% 
bovine-serum-albumin in 0.1 M PBS with 0.001 M EDTA and 0.5%
Tween 80, and then incubated with dilutions of the MAbs followed 
by rabbit anti-mouse IgG conjugated with horseradish peroxidase. 
Each incubation was at 37°C and the strips were washed between 
reagents as described above. The peroxidase substrate used was 
0.5 mg 3,31-diaminobenzidine tetrahydrochloride/ml in 0.02 M 
TRIS/HC1 buffer, pH 7.3, with 0.3 ul H202 (30% solution)/ml (82).
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3.3 Results
3.31 Cell Fractions.
ELISA reactivities of M^ _ bovis fractions with hyperimmune sera 
raised in mice to M.bovis sc38 whole cells were determined. The 
objective of this assay was to optimise the antigen-coating prior 
to screening the MAbs.
Table 1. Results of ELISA screening of
M.bovis sc38 hyperimmune mouse serum with M. bovis sc38 antigens.
Serum dilution
1000 2000 4000
Antigen reciprocal dil.
W (whole cell) 1000 >2.0 >2.0 >2.0
2000 >2.0 >2.0 >2.0
4000 >2.0 1.8 1.1
C (cytoplasmic) 500 >2.0 1.8 1.2
1000 1.7 1.2 0.8
2000 0.8 0.7 0.5
M (membrane) 500 >2.0 1.3 0.8
1000 0.8 0.6 0.4
2000 0.4 0.3 0.2
Results are expressed in spectrophotometer (Titertek) absorption 
units at 480 nm.
Conjugate (Veooo) control - 0.6; Serum control - 0.09
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The results indicate that the optimum concentration of each 
antigen coating for screening MAbs was:
Whole 1/4000
Cytoplasmic Viooo 
Membrane Vsoo
This ELISA format was repeated for conjugate optimisation, with 
the following results:
Table 2. Results of ELISA tests for conjugate optimisation.
Conjugate dilution 
2000 4000
Antigen dil
W 4000 >2.0 >2.0
C 1000 1.7 1.2
M 500 >2.0 >2.0
Results are expressed in spectrophotometer (Titertek) absorption 
units at 480 nm.
. i i i . .
The conjugate dilution of /4000 was consi(*ered optimal.
3.32 MAb hvbridoma screening.
The supernatant fluid from actively growing hybridomas was 
screened by an ELISA test, performed in microtitre plates 
(Dynatec) coated with the JL bovis "i.p." antigen. After the 
second cloning those producing significant ELISA readings (> X2 
background) selected as positive and were transferred to 24-well
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"Costar" plates to grow up in bulk. Aliquots of cells were 
frozen as soon as possible. 151 positive ( > x2 background)
hybridomas were selected for "stage 1" cloning. The antigen- 
panel used for screening the stage-1 clones were: 
cytoplasmic # ?
"Sephadex G-200" #21;
Pig serum;
"i.p." antigen.
A total of 441 hybridomas were developed, of which 151 had 
significant ELISA activity, from which the reserve bank of frozen 
hybrids was created. Of the 151 original hybridomas, 14 were 
retested using the above panel of antigens: those 6 with the 
best ELISA-screening profile were selected for cloning.
Table 3. ELISA results selecting stage-1 MAb clones 08/01/1990
Clone Antigen ELISA value
3G3
2H1
4F2
4H9
5A10
5G4
S
S
C
C
S
S
1.590
1.853
1.271
1.307
>2.0
>2.0
Results are expressed in spectrophotometer (Titertek) absorption 
units at 480 nm.
Control : 0.10
Antigen dilution: 1/2000
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Cloning these 6 original hybridomas produced a total of 210 
hybridoma-lines ('stage-1 clones'). Again 6 of the latter were 
selected for re-cloning: 6 'stage-2 clones' were selected on the 
basis of ELISA retesting.
The monoclonal antibody (MAb) class of the 6 stage-2 clones was 
determined by double immunodiffusion against rabbit antisera to 
mouse immunoglobulin isotypes (Nordic, Sweden). Each MAb cell 
line was cultured to larger volume by dialysis sac growth.
3.33 Immunoblotting.
The "i.p." antigen was subjected to PAGE, then "Western Blotted" 
onto nitrocellulose paper and immunoblotted with the 6 cloned 
MAbs, to characterise the antigen(s) against which they were 
directed. The results shown in Figure 6 illustrate the common 
antigenic epitope against which the "5A10" MAb is directed. The 
estimated molecular weight is 30 kD.
3.34 MAb "5G4".
The affinity chromatography profile produced during the 
purification of MAb 5G4 is shown. The fractions were collected 
and assayed for antibody activity on 29.03.90. This resulted in 
3 batch-pools:
1. #8 ?
2. #7/9/10/11/12;
3. #3/4/5/6.
Detailed results of hybridomas and clones screened positive by 
ELISA are presented below in Tables 4 - 6  inclusive.
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Immunoblot 14.06.1990 Mycoplasma spp.
MAb 5A10 B 1/50 
AFFinity-puriFled G.A.M.
O.A.B. substrate 25mg/50ml TRIS/HCL pH7.2
M. bovis sc38
<* *
IP*
M. bovis 130 M. agalactiae
,66kD
. 45kD 
36kD
-^29kP r 
,24kP,
.20kD,
4 4 .2kJ^
Figure 6.
Immunoblot of H. bovis sc38, M . bov_is 130 
and M. agalactiae with MAb 5A10.
H~H~r
>>
3 S "I
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U- < CD< Z I\1
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Figure 7.
Absorption at 280 ran of the eluate from a 
Protein-A column loaded with MAb 5G4.
Table 4^ Detailed results of hybridomas screened positive.
Fusion 97: M. bovis 22 .12.1989
Table 4a. 01.01 .1990 (43)
Plate-1 P-2 P-3 P-4 P-5
A9 03 A4 15 D1 36 A5 46 A7 60
A10 04 A12 16 D4 37 B2 47 B6 61
D9 09 B9 18 D12 38 B9 48 C2 63
F6 10 Bll 19 E6 40 C4 49 C8 65
C9 22 Ell 41 D7 51 D2 66
CIO 23 G3 42 E4 52 Dll 69
D5 24 G6 43 E8 53 E8 71
E7 25 H6 45 F4 54 F2 72
G8 29 F5 55
G9 30 G5 57
H4 58
H5 59
Table 4b. 02.01 .1990 (53)
P-l P-2 P-3 P-4 P-5 a ;
21 F6 59 A8 66 B5 88 A10 14
B4 25 HI 65 A9 67 B10 89 BIO 16
B9 27 Cl 71 C2 91 CIO 21
D5 32 Fll 78 C8 92 F4 34
E6 35 C12 93 G4 36
G10 42 D4 95 Gil 38
H4 43 E3 97 H3 03
F2 101
G3 106
H7 109
H9 110
H10 111
Hll 112
H12 113
VOl04 P—7 E4 60 A2 67
F4 62 A4 69
G1 65 A7 70
G8 66 All 71
D4 05 B3 73
£7 09 Cl 76
C2 77
Cll 81
D5 82
Dll 85
A12 13 B4 14
C4 16
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Table 4c. 03.01.1990 (14)
P-l
A7
All
B1
C9
C12
E10
F5
F7
G5
G6
G7
03
04 
06 
15 
18 
30
33
34
39
40
41
P-2
A7
El
F9
54
72
83
Table 4d. 04.01.1990 (41)
P-l P-2 P-3
A9 01 A4 05 D1
A10 02 A12 06 D4
D9 03 B9 07 D12
Bll 08 E6
C9 09 Ell
CIO 10 G3
D5 11 G6
E7 12 H6
G8 13
G9 14
P-4 P-5
15 A5 23 A7 35
16 B2 24 C2 37
17 B9 25 C8 39
18 C4 26 D2 40
19 D7 27 Dll 42
20 E4 28 E8 43
21 F5 31 F2 44
22 G5 32 H3 45
H4 33
H5 34
P-6
F7 47
P—7 
A12 
C4
48
50
62
Table 4e. 05.01.1990
*0 1 H P-2 P-3 P-4 *0 l 01
A2 1 A7 59 A8 10 B5 14 A10
B4 2 El 60 A9 11 BIO 15 BIO
B9 3 F6 8 Cl 12 C2 16 CIO
D5 4 F9 61 Fll 13 C8 17 F4
E6 5 HI 9 C12 18 G4
G7 58 D4 19 Gil
G10 6 E3 20
H4 7 F2 21
G3 22
H7 23
H9 24
H10 25
Hll 26
P-6 P-7
E4 33 A2 37
F4 34 A4 38
G1 35 A7 39
G8 36 All 40
B3 41
Cl 42
C2 43
C7 44
Cll 45
D5 46
Dll 47
Table 4f. 08.01. 1990
3D1 1 3E6 2 3G3 3 4F4 4 5H3
6F7 6 7A12 7 2H1 8 3C1 9 4F2
4H9 11 5A10 12 5G4 13
27
28
29
30
31
32
5
10
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Table 5. Detailed results of stage-1 clones screened positive.
Table 5a. 19.01. 1990
2H1 3G3
P-l P-2 P-l P-2
All 1 A2 13 All 24 A5 33
A12 2 B12 14 B5 25 A9 34
B4 3 Cll 15 Cl 26 A10 35
C4 4 D7 16 C12 27 B3 36
D5 5 Dll 17 Dll 28 B8 37
D8 6 E3 18 F7 29 G4 38
DIO 7 E4 19 F12 30 G7 39
E2 8 F4 20 H8 31 H6 40
E7 9 G8 21 Hll 32 Hll 41
F12 10 H3 22
G1 11 H10 23
H6 12
4F2
P-l P-2
A2 42 A1 6
A10 43 A4 62
B1 44 A6 63
B2 45 A10 64
C3 46 B7 65
C12 47 B9 66
D1 48 C2 67
D3 49 C3 68
Dll 50 C12 69
E9 51 Dll 70
FI 52 E2 71
F2 53 F6 72
F5 54 G4 73
G4 55 G8 74
G7 56 G9 75
H3 57 H9 76
H4 58
H7 59
Hll 60
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Table 5b. 21.01.1990
2H1 3G3
P-l
B2
B5
B6
Bll
D3
Dll
G4
G7
P-2
A12
B3
B4
C7
E9
F5
Fll
F12
G1
G10
G12
9
10 
11 
12
13
14
15
16
17
18 
19
P-l
Bll
C3
C9
D6
E2
E12
F8
F9
G4
20
21
22
23
24
25
26
27
28
P-2
A1
All
C12
D7
E9
G3
G10
29
30
31
32
33
34
35
4F2
P-l
A6
B9
Bll
C5
H2
H10
36
37
38
39
40
41
P-2
A12
C8
CIO
D1
D7
E9
42
43
44
45
46
47
Table 5c. 
2H1
P-l P-2
DIO E4 
G8
Table 5d.
2H1
P-l
B3
G12
C8
CIO
D1
23.01.1990 
4F2
C3
D1
H4
E9
H3
A1
A4
A6
A10
24.01.1990 
4F2
P-2
A6
B9
Bll
C3
D1
65
E9
Table 5e. 28.01.1990
4H9 5A10 5G4
P-l P-2 P-l P-2 P-l P-2
H9 B8 G10 B6 A5 B7
E5 F8 All Bll
G12 A12 B12
B4 Cl
B12 CIO
C4 D4
C6 D5
DIO D6
El D8
E5 Dll
G3 El
G10 E7
H2 E10
H6 E12
FI 
G12
Table 5f
4F2
P-l P-2
C3 B9
D1 Bll
A6 C8
CIO
D1
E9
Table 5a. 30.01. 1990
4H9 5A10
P-l P-2 P-l P-2
C9 A1 E4 A5
G8 B5 F2 A12
C5 G5 C7
E10 G7 F6
G10 F8
G12
H4
H8
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Table 6. Detailed results of stacre-2 clones screened
Table 6a. 09.02.1990
2H1D10 4F2D1 5G4D8
P-l P-2 P-l P-2 P-l P-2
All A6 A2 A4 A2 A1
A8 A12 A12 B8 A5 A4
B2 B7 B6 C6 A8 A7
B8 B8 Bll C12 All B1
BIO Dll C8 D3 B2 B3
Cll D12 Cll F10 B5 Bll
D4 E2 D8 G9 B12 C2
E2 Ell E5 C6 Cl
E3 F3 E8 Cll CIO
E6 Fll F7 C12 D2
E7 G2 F9 D4 D4
F3 G1 D5 D5
Gil G6 D7 D8
G12 H2 D9 D9
H10 H9 D10 El
E3 E3
E4 E7
E7 Ell
F3 F5
F5 F6
F10 F10
Fll Fll
F12 F12
G1 G2
G3 G3
G6 G9
Gil G10
H2 H2
H7
H8
Table 6b. 15.02.1990
5A10
E4
F3
Table 6c. 19.02.1990
5A10E4 5A10F3
A1 B1
A2 B2
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TFigure 8.
Absorption at 280 nm of the eluate from a 
Protein-AG column loaded with MAb 2H1.
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Figure 9.
Absorption at 280 nm of the eluate from a 
Protein-AG column loaded with MAb 5A10.
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Figure 10.
Absorption at 280 nm of the eluate from a 
column loaded with MAb 5A10.
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3.4 Discussion
All 441 hybrids were checked for growth, which appeared as small 
clumps of cells. The first screening resulted in some definitely 
positive wells, some possibly weakly positive and some definitely 
negative. The 290 negative hybridomas were discarded but it 
might have been worth keeping some of the intermediate wells. 
The decision to get rid of cells that do not show positivity is 
difficult. It may be that they are not producing very much 
antibody but are never-the-less positive, or the antigen (in the 
antigen preparation) may be in such low concentration that the 
well appears negative.
Retesting 14 of 151 active hybridomas gave a representative 
sample on which to base cloning selection, while reducing the 
workload at a very busy period of monoclonal development.
The number of the best original hybridomas selected for stage-1 
cloning was decided on advice from those experienced in
monoclonal antibody development. This was proven accurate, given 
the workload imposed in retesting the 210 stage-1 clones thus 
created.
The MAb prepared by the caprylic acid-ammonium sulphate method 
was highly purified. Treatment of ascites fluid with caprylic 
acid alone sometimes resulted in an unacceptable amount of 
albumin contamination (as evident on P.A.G.E. slab-gels). The
precipitation of serum proteins by caprylic acid was markedly 
influenced by pH. Essentially, all non-IgG proteins were
completely precipitated by caprylic acid at pH 4.2, and 4.5. At
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pH 4.8, caprylic acid failed to precipitate certain globulins, 
whereas at pH 5.1 even albumin was incompletely precipitated. 
The use of ammonium sulphate after caprylic acid not only removed 
most of the residual albumin, but permitted concentration of the 
immunoglobulin ( 52).
The caprylic acid procedure described here is particularly 
applicable to situations when large amounts of many MAbs need to 
be purified from mouse ascites fluid. Several different pools of 
ascites can be treated at the same time since the procedure is 
simple, and each batch of ascites fluid is kept within one 
vessel. Compared to chromatographic methods, this method 
eliminates the need for manipulations of column fractions and 
reduces the chance of contamination of MAb due to the repeated 
use of the column. Also the expense of column matrices and 
column monitoring equipment are avoided. In addition, the 
capacity of this method is greater than that of most 
chromatographic techniques.
The ability to purify IgGl antibodies with good recovery is an 
advantage over Protein-A Sepharose methods, since IgGl is known 
to have poor affinity for Protein-A (30).
ELISA examination of the 6 stage-2 clones revealed one to be 
directed against media constituents, as reflected by the 
capture-ELISA values for uninoculated broth. Given the known 
incidence of adsorption of media constituents to the mycoplasma 
membrane, this finding is perhaps not entirely surprising (17, 
23, 60, 79). The design of the screening protocols attempted to 
forestall such a problem developing from the porcine serum
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component of the growth media, by substituting of murine serum - 
it was not possible to investigate which component was involved. 
Given the complex nature of the polypeptides constituting 
mycoplasma broth media, this might well be impossible in any 
case.
The occurrence of a monoclonal (MAb 5G4) apparently directed 
against a media constituent was of interest (79). The results of 
the ELISA test which initially showed this cross-reaction would 
appear at first glance to be anomalous. There was no problem 
indicated from the reading for the neat broth well, yet the 1/20 
dilution produced the highest interference level. This may be 
explained by the absence of high pH carbonate coating buffer from 
the neat, undiluted broth which by inference did not coat the 
well of the plate. In contrast, the low dilution containing 
coating buffer did ensure binding of the antigen to the well, and 
thus a reaction.
The literature cites the cross-reactivity of bovine serum with 
mycoplasma antigens of bovine, caprine, avian, and environmental 
sources, with the strongest reaction between M^ _ bovis and 
M. agalactiae (49).
Immunological cross-reactivity among members of the 
Mycoplasmatales is well documented (49). Cross-reactive antigens 
have been associated with culture medium components, with various 
members of the genus, and with other bacteria and viruses. 
Antibodies may be raised directed to medium components on the 
mycoplasmal cell. This could be investigated by comparing ELISA 
reactivity before and after adsorption with culture medium.
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Adsorption is capable of removing reactivity with the medium 
(65.9 %) and removal of over 30 % of the reactivity with
mycoplasmas of non-bovine habitats (M_j_ agalactiae) (49) .
The interfering influence of antibodies directed to an antigenic 
component adsorbable with culture medium obscures the specific 
ELISA reactivity between homologous antigen and antisera. The 
non-specific reactivity observed in ELISA will be hard to 
overcome using antisera raised against conventionally prepared 
mycoplasma cells grown on complex media. This problem has been 
somewhat alleviated in this project by using species-specific 
reagents (murine serum source in growth media) (60).
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Chapter Four.
ELISA Construction and Field Testing.
4.1 introduction
The need for a diagnostic test to detect Mj_ bovis has been 
outlined in Chapter 1. This chapter describes the construction 
of the ELISA test for the detection of JL bovis antigen in milk 
and semen samples. The development of 6 monoclonal antibody 
lines has been described in Chapter 4: their evaluation for use 
in the final diagnostic format of the ELISA is outlined below.
The test format chosen for development was the capture ELISA 
type. This fulfilled the diagnostic requirements, particularly as 
the potential of this assay type for high specificity addressed 
the problem of cross-reactivity between different mycoplasma 
species (10).
Given the recognised cross reaction problem in serological 
diagnosis of mycoplasmal infection, extensive evaluation of the 
test against other mycoplasma species and media is necessary(^60, 
80) .
Having orientated the test development primarily toward 
specificity, the question of sensitivity is then of prime 
importance. The stoichiometry of the chemical reaction between 
streptavidin and biotin may be used as the signal produced by a 
positive reaction in the ELISA test.
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Assessment of the test sensitivity was achieved by comparison of 
field test results with those obtained by conventional isolation 
techniques and from the NAGase mastitic milk ELISA, giving an 
overall impression of the sensitivity of the test developed. 
Testing serial dilutions of inoculated media was another method 
for assessing test sensitivity (8).
4.2 Materials and Methods.
The general protocol of the capture ELISA test is as follows:
1. Coat plates with MAb overnight at 4°C;
2. Capture of Mycoplasma sp. from broths incubated for 2 hours 
at 37°C?
3. Conjugation with biotinylated-MAb (BMAb) by incubation for 2 
hours at 37°C?
4. Develop by the addition of Streptavidin-peroxidase and 
substrate.
4.21 Construction of Final ELISA.
The ELISA was constructed from testing various MAb/BMAb 
combinations by the general protocol outlined above against a 48 
hour broth of M^ bovis sc38, used at Vioo dilution. MAb "SAIO” 
was chosen for use both as the coating monoclonal antibody and 
for biotinylation. The final format of ELISA was as follows:
1. Coat plate caprylic acid treated Viooo "SAIO"
2. Capture broth-dilutions V i o  ” ^lo""7'
3. Develop with V 500 B,,5A10"»
4. V 2000 strePtavidin.
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4.22 MAb "SAIO” Specificity.
MAb "5A10" was extensively tested against all Mycoplasma species 
known to be have common surface membrane antigens. The origin of 
the Mycoplasma species tested by capture ELISA are outlined below 
in Table 7. Cultures were taken from storage at - 70°C and grown 
for 48 hours in standard mycoplasma broth, incubated at 37°C in 
an atmosphere of 10% C02. 0.20 ml of this broth was then
dispensed as the antigen in the ELISA test.
Table 7. Mycoplasma s p p . tested bv MAb 115A10" for serological 
cross-reaction.
Mycoplasma s p . 
M.californicum
M .boviaenita1ium
M.canadense
M. bovis
M.agalactiae 
M.svnoviae 
M.arginini 
M.edwardii
M.alkalens 
M.iners 
M.bovoculi 
M .verecundum 
M.dispar 
M.bovirhinis 
M.anatis 
M. canis
M.felis 
M.fermentens 
M.hvorhinis 
M.pulmonis
isolate origin
162 Bovine semen
M249 Bovine mastitis
383/83 Bovine mastitis
49 Bovine vaginal swab
M197 Bovine mastitis
M314 Bovine mastitis
MC961 Bovine vaginal swab
44 Bovine semen
M128 Bovine mastitis
M1043 Bovine vaginal swab
sc38 Bovine mastitis
130 Bovine calf pneumonia
Sh Bovine mastitis
10131 N.C.T.C.
222/89 Bovine mastitis
221/89 Bovine mastitis
422/88 Bovine mastitis
10123 N.C.T.C.
10127 N.C.T.C.
10129 N.C.T.C.
10132 N.C.T.C.
MM5d Canine vaginal swab
10135 N.C.T.C.
10165 N.C.T.C.
10141 N.C.T.C.
10145 N.C.T.C.
10125 N.C.T.C.
10118 N.C.T.C.
Stormont
MM50d Canine nasal swab
MM25d Canine nasal swab
MM40c Feline nasal swab
10117 N.C.T.C.
MP621 Porcine lung
MM70R Rat lung
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4.23 Sensitivity Assay.
Mycoplasma broth was inoculated and incubated for 48 hours to 
achieve log phase growth. Serial ten-fold dilutions were made 
and colony counts performed on Friis agar plates. These 
dilutions were used as antigen for a capture-ELISA format.
4.24 N-acetvlglucosamide.
The estimation of the level of N-acetylglucosamide (NAGase) in 
milk has been shown to be indicative of cell damage, and has been 
found to correlate well with milk cell counts (MCC) . As such, 
this is an enzymatic method for the detection of mastitis. The 
test uses the enzymatic release of fluorochrome 4-methyl 
umbelliferone (6) .
Milk samples.
A total of 78 milk samples were provided from Dr. H Putzner, 
Institute for Bacterial Animal Diseases, Jena, Germany. Each 5 
ml sample was supplied in a heat-sealed glass vial, constituting 
a daily single-quarter sample from an individual cow which had 
been experimentally infected intracisternally with a local strain 
of bovis. The results of reisolation provided here are
culture protocols performed at source. Similarly, the assessment 
of gross mastitic change in the milks was performed at collection 
and graded, if visible, as "slight" - +, or "gross" - ++.
NAGase examinations were carried out on the milks by Dr. H Ball 
at Stormont after the studies described here were completed. The
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method is described here and the results presented. Duplicate 
20 ul aliquots of milk and 40 ul of 2.25 mM 4-methyl 
umbell*feryl-N-acetyl-B-D glucosamide (MUFAG) in 0.25 M citrate 
buffer (pH 4.6) were dispensed into the wells of microtitre 
plates. Fluorescent standards for each batch of milk samples 
were 7.5, 15 and 30 uM 4-methyl umbelliferone in 0.25 M citrate
buffer, pH 4.6, and dilutions of a standardised mastitic milk. 
Uninoculated MUFAG substrate was also included as a control. 
Incubation was for 30 min. at 4°C. The NAGase reaction was 
terminated by addition of 200 ul of 0.2 M glycine NaOH buffer (pH 
10.7) to both test and standard wells. Emitted fluorescence was 
read by a fluorometer:- wells were scored as positive or negative 
in relation to the controls. A positive in either of the 
duplicate wells scored the individual sample as positive. A cut­
off point of >400 000 cells/ml was taken for MCC: milk with MCC 
levels above this were regarded as mastitic. The majority of 
MCCs of > 400 000 had detectable NAGase activity (6).
4.3 Results.
4.31 MAb "SAIO" Specificity.
The only significant activity noted from the ELISA readings were 
with all the M*. bovis isolates from various sources, and the M. 
aaalactiae type culture. No other cross-reactions were observed.
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Table 8. Serological cross-reaction of MAb 5HA10" with M. bovis 
and M. aaalactiae.
M.aaalactiae M. bovis sc38
B5A10
500 0.4 1.0
1000 0.3 0.9
The literature cites the cross-reactivity of bovine serum with 
mycoplasma antigens of bovine, caprine, avian, and environmental 
sources, with the strongest reaction between Mj_ bovis and M. 
aaalactiae (17, 36, 77, 80).
4.32 Sensitivity Assay.
Table 9. MAb 115A10H sensitivity assay by serial dilution of 48 
hour inoculated broths.
M. bovis strain
sc38 130
Broth diln.
10 0.3 0.4
102 0.090 0.102
103 0.097 0.09
Conjugate-control absorption: 0.100
Test is sensitive for broth dilution of 1/10, representing a 
sensitivity of 108 cfu/ml.
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Table 10. Detailed ELISA results for experimental milks.
Table 10a. Cow no. 1
Days Milk
p.i. Clots
; 1
2 +
3
7 ++
; 10 ++
f 14 ++
17 ++
21
| 24 ++
28 ++
31 ++
35 ++
ELISA Reisolation
M. bovis NAGase (log10)
7
7
7
7
7
7
7
7
7
7
7
7
7
12 
6
50.0
38 ++ - +
No of NAGase +ve IL. bovis isolations 
No of Ms. bovis ELISA +ve isolations 
M. bovis ELISA % sensitivity
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Table 10b. Cow no. 2
Days Milk ELISA Reisolation
p.i. Clots Ms. bovis NAGase (log10)
1 + 4
7 ++ + + 7
10 + + +  + 7
14 ++ + + 7
17 ++ + + 7
21 ++ + + 7
24 ++ + - 7
28 ++ + + 7
31 ++ + + 7
35 ++ + + 7
38 ++ + + 7
No of NAGase +ve bovis isolations 11
No of IL bovis ELISA +ve isolations 10
M. bovis ELISA % sensitivity 90.9
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Table 10c. Cow no. 3.
Days 
p. i.
1
Milk ELISA Reisolation
Clots Us. bovis NAGase (log10)
3 + 7
7 + + + 7
10 ++ + + 7
14 + 3
17 2
21 ++ - - 3
I 24
28
31
35
38
No of NAGase +ve JL_ bovis isolations 
No of Jit. bovis ELISA +ve isolations 
M. bovis ELISA % sensitivity
8
2
25
Table lOd. Cow no. 2
Days Milk ELISA
p.i. Clots ML. bovis NAGase
10
14
17
21
24
28
31
35
38
No of NAGase +ve 1L_ bovis isolations 
No of Mi. bovis ELISA +ve isolations 
M. bovis ELISA % sensitivity
Reisolation
(i°g10)
0
0
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Table lOe. Cow no. 8
Days Milk ELISA Reisolation
p.i. Clots J!a_ bovis NAGase (log10)
10
14
17
21
24
28
31
35
38
No of NAGase +ve IL_ bovis isolations 8
No of MU. bovis ELISA +ve isolations 7
M. bovis ELISA % sensitivity 87.5
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Table lOf. Cow no. 9
Days Milk ELISA Reisolation
p.i. Clots Mj_ bovis NAGase (locfio)
10
14
I 17i
i
t
( 21
24
28
i 31
35
38
No of NAGase +ve Mj_ bovis isolations 8
No of M*. bovis ELISA +ve isolations 2
M. bovis ELISA % sensitivity 25
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4.33 Results of ELISA examination of milk samples.
Table 11. Summary of ELISA results for experimental milks.
No of NAGase +ve M*. bovis isolations 47
No of Mi. bovis ELISA +ve isolations 27
M. bovis ELISA % sensitivity 57.5
These results indicate a sensitivity of approximately 107 
organisms/ml:- higher than with broth culture.
In general, the ELISA results detected antigen where it had been 
demonstrated by standard cultural techniques. In all cases, the 
ELISA detected antigen in milks where it had been isolated at a 
concentration of 10*^  organisms per ml. No isolations were made 
from milks where the reisolation was less than that level. The 
detailed results are presented in Tables 10 &x\d II.
4.34 N-acetvlalucosamide.
These results would also tend to suggest that the sensitivity of 
the ELISA test is c. 107 c.f.u./ml.
4.4 Discussion
The construction of the capture ELISA initially was impaired 
by the poor titre achieved from in vitro production of 
large volumes of monoclonal antibody as sac fluid. The sac fluid 
produced from MAb 5A10 required a titre of 1/50, whereas the
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production of ascites fluid from the same line achieved a titre 
of 1/1000 for the same test format.
The NAGase ELISA was carried out on the German experimental 
milks in the V.R.L., Belfast after the end of the project. The 
cultural examination for M_i_ bovis was performed in East Germany, 
and is thus the source of the data on reisolation. The results 
of NAGase and cultural examination carried out by others are 
included here and aid the interpretation of results using the 
M. bovis ELISA developed in this study. It is interesting to 
note that the test sensitivity appeared to be an order of 
magnitude higher basing the measurement on testing clinically 
affected milks from acute cases, compared to estimations from 
serial broth dilutions. The fact that the M^ _ bovis ELISA did not 
pick up any positive-culture milks earlier than day 3 or after 
d38 is also of interest with a view to the use of the test in the 
case of a herd epizootic.
Further work to improve the sensitivity of the test would 
obviously be desirable. Investigation of hybridoma reserve lines 
held in frozen storage might produce a monoclonal which would 
produce a more sensitive capture ELISA. On the basis of the 
previous experience with the development of a capture ELISA to 
detect Mj. californicum. pre-processing the milk sample might 
prove worthwhile. In this context, centrifuge collection of the 
milk cells, and inoculation into broth might prove beneficial to 
the overall sensitivity. Obviously the detracts from the 
potential of using the test for screening subclinical chronic 
carriers in a herd.
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Chapter 5.
General Discussion.
5.1 Present Study
The objective of the study was achieved by the development of an 
antigen capture ELISA test for the rapid detection of 
M. bovis in milk, with a sensitivity of approximately 108 cfu/ml 
of broth culture. The test, as currently used, has good 
specificity, with cross reaction being detected only to 
M. agalactiae (80) . As the latter is not an agent associated 
with bovine mastitis, this cross-reactivity does not invalidate 
this ELISA as a rapid diagnostic test. Indeed, it opens the 
possibility of testing sheep and goats for M_;_ agalactiae. 
Although this test has been developed to assay for the presence 
of antigen in milk samples, the MAb technique could be used to 
isolate the antigenic epitope from the original antigen 
fractionation, thus allowing for the construction of an ELISA to 
test for serum antibodies directed against bovis (17, 23, 33, 
36, 77, 83) .
During development of the monoclonals, it became apparent one of 
the 6 cloned hybridomas was directed against media constituents. 
The origin of the antigenic stimulation by broth constituents may 
have arisen from their incorporation in the mycoplasmal membrane 
prepared in Chapter 2 (80). This is a recognised problem as
cited in the discussion of Chapter 3, having been manifest in 
previous work by the incorporation of porcine serum constituents
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(10) . The early screening of hybridomas in Chapter 3 sought to 
avoid this problem by directly testing for activity against 
porcine serum. In addition, the immunising antigens were cultured 
in broths supplemented with murine serum. The serum necessary to 
grow the cultures for antigen preparation was of equine origin 
(79).
5.2 Areas for Further Investigation.
Assessment of the test sensitivity was by comparison of cultural 
isolation and NAGase with the mastitis ELISA, as documented in 
Chapter 4. The results compared favourably with experimental 
results using 48-hour broths, indicating a sensitivity level of 
about 107 cfu/ml. This might be improved by the selection of 
other lines for cloning, which would necessitate screening more 
of the original stage-1 clones. The decision to embark on this 
course was made when the selected clones were not showing 
satisfactory sensitivity in the early stages of test formulation. 
The sensitivity of the test may have been affected adversely by 
the presence of homologous antibody (whey IgG & IgA) in the 
clinical milks used for field testing, especially given the 
chronic nature of the infection in some of the samples. 
Literature cites ELISA detected antibodies against M.bovis at 
titres up to 1:25 000 in milk from cows with mastitis. An
indirect haemagglutination test (IHT) detected titres up to 
1:8192 in milk from the same cows (44).
The literature cites the use of culture-amplified EIA procedure 
as a standard method of enhancing the sensitivity of the ELISA
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test developed. Compared to standard cultural techniques, 
improvements in sensitivity from 65 to 85% have been recorded 
(55) . Another technique which might prove beneficial would be 
ultrasonication of such 18-hour broth cultures. This might
increase the number of epitopes available to the monoclonal
antibody, and thus the signal produced in the ELISA format.
The theory of making more epitopes available for capture might be 
exploited by capturing continuously growing culture. This might 
be achieved by mixing the milk sample 1:1 with broth and 
incubating the mixture overnight in the ELISA plate wells which 
had previously been coated for the capture format. The potential 
of this adaptation exploits the fact that M^ . bovis is known to be 
one of the most rapidly growing of the mycoplasmas, thus creating 
a larger amount of antigen in overnight capture testing.
Since a monoclonal antibody has successfully been developed 
against an epitope of M_j_ bovis. it would be possible to use it in 
a minigel MAb immunoblot assay rather than that of an EIA (55) . 
Following ultrasonication of the test sample, the immunoblot
technique would show the detection of the target 3 0 kD epitope.
The actual sensitivity of detection of this protein would be 
the subject of further investigation. An additional advantage of 
the immunoblot assay is its ability to detect antigen already 
complexed with antibody. It bovis antigen in the form of immune 
complexes may not be detected by conventional immunoassays or by 
culture. In addition, this assay is not affected by Protein A 
(SpA) binding of monoclonal antibody by Staphylococcus s p p . found 
in the test specimen (milk) (50). The system has been capable of
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achieving a sensitivity equivalent to 200 ccu/ml by standard 
culture techniques. Many hybridomas were frozen down during the 
development of the test, and are available for further study.
Perhaps one of these would give a higher sensitivity, or unique
specificity for It bovis if further time was available. The 
possibility of incorporating it with MAb "5A10" in an
immunoblot technique would have potential, especially were it to 
be directed against an an epitope other than the 30 kD target: 
this might increase the sensitivity to the point of using the 
test for detection of individual carrier cows (82).
5.3 Conclusion.
Given this level of sensitivity, it appears the test is suitable 
as a diagnostic tool for herd testing following the 
identification of the index case in an M_;_ bovis mastitis 
outbreak. In its present form, the test would seem not to
possess the level of sensitivity necessary to reliably detect
subclinical carriers, in the case of screening individuals prior 
to entry to a clean herd. Further evaluation of the role of milk 
antibody in chronically infected or convalescent cows would be 
necessary to determine if there was an antibody interference 
component to the level of sensitivity achieved with this sort of 
clinical milk sample.
90
Appendix
PAGE Gel staining method.
1. 500 ml distilled water
50.0 g trichloroacetic acid
17.5 g 5-sulphosalicylic acid
150.0 ml methanol
Immerse gel for 1 hour.
2. 500 ml distilled water
150.0 ml methanol
60.0 g trichloroacetic acid
Immerse gel for 30 minutes.
3. 500 ml distilled water
50 ml ethanol
25 ml acetic acid
Immerse gel for 3 0 minutes.
4. 600 ml distilled water
150.0 ml methanol
60.0 g trichloroacetic acid
19.2 g developer (BIO-RAD)
Immerse gel for 30 minutes.
5. 180 ml deionised water
20.0 ml oxidiser concentrate (BIO-RAD)
Swirl over gel for 10 minutes.
6. Wash in changes of deionised water for 30 minutes.
7. 180 ml deionised water
20.0 ml silver reagent (BIO-RAD)
Agitate over gel for 30 minutes.
8. Quickly was off silver reagent with 200 ml deionised water.
9. Add 200 ml developer (BIO-RAD). Swirl until solution turns
yellow/brown, then pour off and repeat twice at 5 minute
intervals.
10. Stop the reaction by covering the gel for 5 minutes with
5% acetic acid solution.
11. Store the gel in 40% ethanol.
91
PAGE Gels
Gel buffer, pH 8.9
TRIS 18.15 g 
SDS 0.40 g 
H20 to 100 ml.
Spacer Gel, pH 6.7
TRIS 5.9 g 
SDS 0.4 g 
H20 to 100 ml.
Tank Buffer
TRIS 3.16 g 
Glycine 2.0 g 
SDS 1.0 g 
H20 to 500 ml.
Boiling Mixture
Spacer gel buffer 1.0 ml
25 % SDS in H20 0.8 ml
B-mercaptoethanol 0.5 ml
glycerol 1.0 ml
Stacking gel
Aery1amide 1.0 ml
Spacer gel 1.5 ml
H20 3.5 ml
"AP" 0.065 ml
"Temed" 0.004 ml
12.5 % Resolving Gel.
Acrylamide 10.0 ml
Gel buffer 6.0 ml
H20 4.4 ml
"AP" 0.200 ml
"Temed" 0.020 ml
Glycine 3.60 ml
Total volume 24.0 ml
Bromophenol blue 0.060 ml
0.060 ml fraction + 0.0010 ml bromophenol blue solubiliser were 
loaded into the wells of the stacking gel. Fractions for PAGE 
were run in HEPES buffer, pH 7.20 + 0.10 % SDS.
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Western Blotting
1. Prepare 7.5 % polyacrylamide gel and prepare sample:boiling
mixture 2:1. Boil 3 minutes, cool and add to gel. Run at
30 mA.
2. Western Blot overnight as follows:
Soak "Scotch Brite pads", filter paper and nitrocellulose in
blot buffer.
3. Assemble in order: 
"Scotch Brite"; 
x2 filter paper; 
gel;
nitrocellulose; 
x2 filter paper; 
"Scotch Brite".
4. Put into blot apparatus with the nitrocellulose TOWARDS the 
ANODE.
5. Wash nitrocellulose in distilled water and air dry. Mark on
the nitrocellulose the outline of the gel (corners, top and
which side was next the polyacrylamide gel).
6. When dry, cut the nitrocellulose paper into strips. Put
into individual Petri dishes and block using 2.5 ml per dish
of PTNE + 5 % horse serum. Incubate at 37*C for 1 hour.
7. Add sera to dishes. ( V 50 sera = ac^ d 0.050 ml neat sera to
2.5 ml PTNE).
8. Incubate for 2 hours at 37 *C.
9. Wash strips several times with PTNE.
10. Add 2.5 ml conjugate. Incubate 1 hour at 37^C.
11. Wash with several changes of PTNE.
12. Add substrate and leave for 5 minutes before rinsing in
distilled water. Air dry strips.
PTNE
PBS 100.0 ml
NaCl 2.0 g
EDTA 1.0 ml
10 % "Tween 80" 5.0 ml
Horse serum 5.0 ml
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Blot Substrate
0.020 M TRIS (0.242 g TRIS/100 ml distilled water, pH 7.2)
50.0 mg DAB (3,3'-diaminobenzidine tetrahydrochloride)
0.033 ml hydrogen peroxide.
Blot buffer
25 mM TRIS ( 9.105 g/41)
112 mM glycine ( 57.656 g/41)
20 % methanol (200.0 ml/41)
7.5 % Acrylamide gel
Aery1amide 9.0 ml
Gel buffer 9.0 ml
Water 18.0 ml
"AP” 0.225 ml
"Temed" 0.015 ml
0.1 M Phosphate buffer, pH 8.0 -
0.1 M Na2HP04 + 0.1 M NaH2P04
0.1 M Citrate buffer, pH 4.0 -
0.1 M trisodium citrate + 0.1 M citric acid
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